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NOTES
1. All the temperatures are expressed in degree centigrade (0C).
2. Melting points of all the compounds are uncorrected and
have been recorded by open capillary method.
3. Room temperature, wherever mentioned, normally corresponds
to 280 - 33 0C.
4. Silica gel-G was used for preparing the TLC plates using
different solvent systems.
5. Infra red spectra  of all the compounds were scanned on
SHIMADZU-FOURIER TRANSFORM INFRA RED(FTIR) -
8400 Spectrophotometer using KBr disc.
6. PMR Spectra were recorded on BRUKER Spectrophotom-
eter(400 MHz) using TMS as a internal standard and CDCI3,
and DMSO-d6 as solvents.
7. 13C NMR Spectra were recorded on BRUKER Spectropho-
tometer(400 MHz) using CDCI3,and DMSO-d6 as solvents.
8. MASS spectra were recorded on SHIMADZU-GCMS-QC-
2010.
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            A  brief summary of  the work to be incorporated in the thesis
entitled  “STUDIES ON SYNTHETIC DRUGS’’ has been summarized as
under.
( I )   STUDIES ON  PYRAZOLO [3,4-d] PYRIMIDINES.
( II )   STUDIES ON PYRIMIDINES.
( III )   STUDIES ON THIENO [3,2-C] PYRAZOLES.
( I )   STUDIES ON  PYRAZOLO [3,4-d] PYRIMIDINES.
PART - I : STUDIES ON  PYRAZOLO [3,4-d] PYRIMIDINES.
Pyrazolo [3,4-d] pyrimidines represents one of the most active classes
of compounds possessing a wide spectrum of biological activities viz.,
anticancer, anti-HIV, antitumor, antiviral, antiparasitic etc., Pyrazolo[3,4-d]-
pyrimidines can be used as a chemotherapeutic agent against neurosfora. It
was thought  worthwhile to synthesize some newer pyrazolo [3,4-d] pyrimidines
which can be summarized as under.
SECTION - I   :Preparation and biological evaluation of  3-Isopropyl-4-
   substituted phenyl-1,4,5,7-tetrahydro-6H-pyrazolo [3,4-d]-











R = Substituted Phenyl
3-Isopropyl-4-substituted phenyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-d]-
pyrimidin-6-ones (Ia-j) have been synthesized by the condensation of different
substituted benzaldehydes, 5-isopropyl-2,4-dihydro-3H-pyrazol-3-one and urea
in the presence of catalytical amount of conc. acid.
Synops i s . . . ,  “  S tud i e s  on  Synthet i c  Drugs . ” 2
SECTION - II :Preparation and biological evaluation of  3-Isopropyl-4-
    substituted phenyl-1,4,5,7-tetrahydro-6H-pyrazolo [3,4-d]-











R = Substituted Phenyl
3-Isopropyl-4-substituted phenyl-1,4,5,7-tetrahydro-6H-pyrazolo [3,4-d]-
pyrimidine-6-thiones (IIa-j) have been synthesized by the condensation of
different substituted benzaldehydes, 5-isopropyl-2,4-dihydro-3H-pyrazol-3-one
and thiourea in the presence of catalytical amount of conc. acid.
   
SECTION - III :Preparation and biological evaluation of 3-Isopropyl-4-
    substituted phenyl-1,4,5,7-tetrahydro-6H-pyrazolo [3,4-d]-











R = Substituted Phenyl
3-Isopropyl-4-substituted phenyl-1,4,5,7-tetrahydro-6H-pyrazolo [3,4-d]-
pyrimidin-6-imines (IIIa-j) have been synthesized by the condensation of
different substituted benzaldehydes, 5-isopropyl-2,4-dihydro-3H-pyrazol-3-one
and guanidine hydrochloride in the presence of catalytical amount of conc.
acid.
SECTION - IV :Preparation and biological evaluation of 3-Isopropyl-4-
     substituted phenyl-1-phenyl-1,4,5,7-tetrahydro-6H-
     pyrazolo[3,4-d] pyrimidin-6-ones.










R = Substituted Phenyl
3-Isopropyl-4-substituted phenyl-1-phenyl-1,4,5,7-tetrahydro-6H-
pyrazolo[3,4-d]  pyrimidin-6-ones (IVa-j) have been synthesized by the
condensation of different substituted benzaldehydes, 5-isopropyl-2-phenyl-2,4-
dihydro-3H-pyrazol-3-one and urea in the presence of catalytical amount of
conc. acid.
SECTION - V :Preparation and biological evaluation of 3-Isopropyl-4-
    substituted phenyl-1-phenyl-1,4,5,7-tetrahydro-6H-










R = Substituted Phenyl
3-Isopropyl-4-substituted phenyl-1-phenyl-1,4,5,7-tetrahydro-6H-
pyrazolo[3,4-d ] pyrimidine-6-thiones (Va-j) have been synthesized by the
condensation of different substituted benzaldehydes, 5-isopropyl-2-phenyl-2,4-
dihydro-3H-pyrazol-3-one and thiourea in the presence of catalytical amount
of conc. acid.
SECTION - VI :Preparation and biological evaluation of 3-Isopropyl-4-
     substituted phenyl-1-phenyl-1,4,5,7-tetrahydro-6H-
     pyrazolo[3,4-d] pyrimidin-6-imines.









    (VIa-j)
R = Substituted Phenyl
3-Isopropyl-4-substituted phenyl-1-phenyl-1,4,5,7-tetrahydro-6H-
pyrazolo[3,4-d ]pyrimidin-6-imines (VIa-j) have been synthesized by the
condensation of different substituted benzaldehydes, 5-isopropyl-2-phenyl-2,4-
dihydro-3H-pyrazol-3-one and guanidine in the presence of catalytical amount
of conc. acid..
( II ) STUDIES  ON   PYRIMIDINES
PART -  II  :  STUDIES   ON  PYRIMIDINES
Pyrimidines represents one of the most active classes of compounds
possessing a wide spectrum of biological activities viz., significant in vitro
activity against unrelated DNA and RNA viruses including Polio and Herpes
viruses,  diuretics, antitubercular, antihypertensive. Some pyrimidines, which
occurs as natural products like nucleic acids and vitamin-B and can be used
as therapeutic agents for the treatment of AIDS and antitumor.  In view of getting
better theraputic agent of  pyrimidines  it was thought worthwhile to synthesize
some newer pyrimidine derivatives which can be summarized as below.














R, R1 = Substituted Phenyl
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6-Isopropyl-N-substituted phenyl-2-oxo-4-substituted phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamides (VIIa-j) have been synthesized by the
condensation of different substituted benzaldehydes, 4-methyl-N-substituted
phenyl-3-oxopentanamides and urea  in the presence of catalytical amount of
conc. acid.
SECTION - II :Preparation and biological evaluation of 6-Isopropyl-5-
    [N - (subst i tu ted  phenyl ) ] -5 -carboxamido-4-ary l -2 -












R, R1 = Substituted Phenyl
6-Isopropyl-N-substituted phenyl-4-aryl-2-thioxo-1,2,3,4-tetrahydro
pyrimidine-5-carboxamides (VIIIa-j) have been synthesized by the condensation
of different  substituted benzaldehydes, 4-methyl-N-(substituted phenyl)-3-
oxopentanamides and thiourea  in the presence of catalytical amount of conc.
acid.
SECTION - III :Preparation and biological evaluation of 2-Imino-6-
    isopropyl-5-[N-(substituted phenyl)]-carboxamido-4-aryl-












R, R1= Substituted Phenyl
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2-Imino-6- isopropyl -N-substituted phenyl-4-aryl-1,2,3,4-tetrahydro
pyrimidine-5-carboxamides (IXa-j) have been synthesized by the condensation
of different substituted benzaldehydes, 4-methyl-N-substituted phenyl-3-
oxopentanamides and guanidine hydrochloride in the presence of catalytical
amount of conc. acid.
( III ) STUDIES ON THIENO [3,2-c] PYRAZOLES
PART - III : STUDIES ON THIENO [3,2-c] PYRAZOLES
Thieno [3,2-c] pyrazoles are one of the most active class of compounds
possessing diverse biological activity viz., anticancer, anti-HIV, antitumor,
diuretic, antipyretic and antimicrobial. Prompted by above facts, some newer
thieno [3,2-c] pyrazoles have been prepared which can be summarized as
under.
SECTION - I :Preparation and biological evaluation 5-Substituted-
   benzoyl-3-methyl-1-phenyl-1,5-dihydropyrazolo[3',4':4,5]-










R = Substituted Phenyl
5-Substituted benzoyl-3-methyl-1-phenyl-1,5-dihydro pyrazolo[3',4':4,5]-
t h i eno [2 ,3 -c ] pyrazo l -7-amines  (Xa-j) have been prepared by the
cyclocondensation of 5-amino-3-methyl-1-phenyl-1H-thieno [3,2-c] pyrazole-
6-carbonitrile and  different substituted phenyl acid hydrazides in the presence
of gl. acetic acid.
SECTION - II :Preparat ion  and b io logica l  eva luat ion  3 -Methy l -6 -
    substi tuted phenyl-1-phenyl-1,5,6,7-tetrahydro-8H-
    pyrazolo [3',4':4,5] thieno [2,3-d] pyrimidin-8-ones.









R = Substituted Phenyl
3-Methyl-6- subst i tuted phenyl-1-phenyl-1,5,6,7-tetrahydro-8H-
pyrazolo [3',4':4,5]thieno[2,3-d]pyrimidin-8-ones (XIa-j) have been prepared
by the cyclocondensation of 5-amino-3-methyl-1-phenyl-1H-thieno[3,2-c]
pyrazole-6-carbonitrile and different substituted benzaldehydes in the presence
of conc. sulfuric acid in gl. acetic acid.
SECTION -III :Preparation and biological evaluation of 3,6-Dimethyl-6-
    substituted phenyl-1-phenyl-1,5,6,7-tetrahydro-8H-










R = Substituted Phenyl
3,6-Dimethyl-6-substituted phenyl-1-phenyl-1,5,6,7-tetrahydro-8H-
pyrazolo[3',4':4,5]thieno[2,3-d]pyrimidin-8-ones (XIIa-j) have been prepared by
the cyclocondensation of  5-amino-3-methyl-1-phenyl-1H-thieno [3,2-c]
pyrazole-6-carbonitrile and  different substituted acetophenones in the
presence of conc. sulfuric acid in gl. acetic acid.
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PURIFICATION AND STRUCTURAL CHARACTRISATION:
The purity of all compounds (Ia-j to XIIa-j) have been screened by thin
layer chromatography using two different solvent systems (Rf1 & Rf2). The
constitution of newly synthesized compounds (Ia-j to XIIa-j) have been
delineated by  elemental analysis, FT-IR, 1H NMR and Mass spectoscopy.
ANTIMICROBIAL ASSAY:
The purified organic compounds (Ia-j to XIIa-j) have been screened for
their in vitro therapeutic assay like antibacterial activities towards Gram
possitive and Gram negative bacterial strain and antifungal activity towards
fungal strain at different concentrations (Minimum Inhibitory Concentration).
The biological activities of synthesized compounds have been compared with
standard drugs at different concentrations.
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STUDIES ON SYNTHETIC DRUGS
(A) Drug
The word drug is derived from the French word “drogue” which means
‘a dry herb’. It is the single active chemical entity present in a medicine that
is used for diagnosis, prevention, treatment / cure of a disease. This dis-
ease oriented definition of drug does not include contraceptives or use of
drugs for improvement of health. According to “WHO” a drug may be defined
as “Any  substance or product which is used or intended to be used for modi-
fying or exploring physiological system as pathological status for the benefit
of the recipient”.
(B) Pharmacology
Pharmacology is the science of drugs. In a broad sense, it deals with
interaction of exogenously administered chemical molecules (drugs) with
living system. It encompasses all aspects of knowledge about drugs, but most
importantly those that are relevant to effective and safe use for medicinal
purposes. For thousands of years most drugs were crude natural products of
unknown composition and limited efficiency. Only the over effects of these
substances on the body were rather imprecisely known, but how the same were
produced was entirely unknown. Over the past 100 years or so, drugs have
been purified, chemically characterized and a vast variety of highly potent and
selective new drugs has been developed. The two main divisions of
pharmacology are pharmacodynamics and pharmacokinetics.
(a) Pharmacodynamics : It is derived from the Greek word “dynamic”
means power. What the drugs does to the body? This includes physiologi-
cal and biochemical  ef fects of  drugs and thei r  mechanism of  act ion
at macromolecular / sub cellular organ systems.
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(b) Pharmacokinetics : It is derived from the Greek word ‘Kinesis’
means movement. What the body does to the drug ? This refers to move-
ments of the drug in and alternation of the drug by the body; includes ab-
sorption, d ist r ibut ion,  b inding /  local izat ion /  s torage,  b iotransforma-
t ion and excretion of the drug.
Some other important aspects of pharmacology are given as under
:
* Pharmacotherapeut ics  :  I t  i s  t he  app l i ca t i on  o f  pha rmaco-
dynamic information together with knowledge of the disease for its
prevention, mitigation or cure.
* Clinical  Pharmacology :  I t  is  the sc ient i f ic  s tudy of  drug in
man. I t  inc ludes pharmacodynamic and pharmacokinet ic  inves
tigation in healthy volunteers and in patients; evaluation of efficiency
and safety  o f  d rugs  and  compara t i ve  t r i a l s  w i th  o the r fo rms
o f  t rea tmen ts ;  surveillance of patterns of drug uses, adverse
effects, etc.
* Chemotherapy : It is the treatment of systemic infection / malignancy
wi th speci f ic  drugs that  have se lect ive tox ic i ty  for  the in fect
ing organism / malignant cell with less effect on the host cells.
?  Drugs in general, can thus be divided into :
* Pharmacodynamic agents :  These are chemical substances
designed to have pharmacodynamic effect in the recipient.
* Chemotherapeutic agents : These are chemical substances designed
for the treatment of infectious diseases or by the proliferation of malignant cells.
(c) Essential Drug Concept: The ‘WHO’ has defined Essential Drugs
as “those that satisfy the healthcare needs of majority of the population; they
should therefore be available at all times in adequate amounts and in
appropriate dosage form”.
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I t  has been real ized that  only a handful  of  drugs out of  the
multitude available can meet the health needs of majority of the people in any
country, and that may be well tested and cheaper drugs are equally (or more)
efficient and safe as their newer more expensive congeners. For optimum
utilization of resources, governments (specially in developing countries) should
concentrate on these drugs by identifying them as Essential Drugs. The “WHO”
has laid down criteria guide selection of an essential drug :
(I) Adequate data on its efficiency and safety should be available from
          clinical studies.
(II) It should be available in a form in which quality, including bioavailability and
stability on storage can be assured.
(III) Its choice should depend upon pattern of prevalent diseases; avail
ability  o f  fac i l i t ies  and t ra ined personne l ;  f inanc ia l  resources;
genet ic ,  demographic and environmental factors.
(IV) In case of two or more similar drugs, choice should be made on the
basis of their relative efficiency, safety, quality, price, availabil ity
and cost benefit ratio should be a major consideration.
(V) Choice may also be influenced by comparative pharmacokinetic proper
ties and local facilities for manufacture and storage.
(VI) Most essential drug should be single compound. Fixed ratio combina
tion products should be included only when dosage of each ingredient
meets the requirements of a defined population group, and when the
combination has a proven advantage.
(VII) Selection of essential drug should be a continuous process which should
take into account the changing priorities for public health action, epide-
miological condition as well as availability of better drugs/ formulations
and progress in pharmacological knowledge.
(C)  Drug Development
Many natural products by trial and error, came into practise for combat-
ing human ailments existent during early human observation. With the advent
of    modern scientific approach, various plant medicines came under
chemical scrutiny, ultimately leading to the isolation of active principles since
early.
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Such compounds either in extract form or in pure form became a part of
pharmacopoeias. For instance, though the Chinese drug, Mauhang was in use
for over 5000 years for the treatment of various types of fever and respiratory
ailments, its active principle, Ephidrine was isolated in 1887. In 1925 chemi-
cal investigations followed by pharmacological evaluation led this compound
into the modern medicine. Similarly during this period, urea stibamine was
introduced as the first drug in 1920 for the treatment of Kala-azar. In 1930, De
Rauwolfia preparation were first employed for sedative and hypotensive prop-
erties.
A drug is a substance having abnormal effect on certain body functions
eg. Strychnine stimulates the action of heart and aspirin retards its action.
Since both of them effects abnormally, the two substances are known as drugs.
Chemical    sciences contributed extensively new discoveries leading to use-
ful drugs since after 1930. The modern concept of drug discovery started in
1933 by Gerhand Domagk with his finding of “Prontosil Red”, a compound
responsible for the antibacterial activity. The advent of sulphonamides drew
the attention for the different activities of various chemicals for bacterial and
human cells, this important factor prompted Florey and Chain in 1939 to in-
vestigate penicillin which was discovered ten years earlier by Alexander
Fleming. The spectacular chemotherapeutical properties of penicillin and its
dramatic war-time development for the treatment of wounds made penicillin,
a most commonly used inexpensive drug.
           A large number of important drugs have been introduced during the
period of 1940 to 1980. This period is known as “Golden period” of new drug
discovery. Thus starting from 1933 - the first antibacterial drug prontosil lead-
ing to various  sulpha drugs ; 1940 – penicillin ; 1945 – chloroquine – anti-
malarial ; 1950 – Methyldopa – anti-hypertensive; 1967 – chlorothiazine
-diuretic; 1958 - adrenergic beta blockers coronary vasodilatory; 1960 - semi
synthetic penicillin -antibacterial; 1965 -trimethoprim-antimicrobial;1967-
disodium chromoglycoate - antiallergic; 1972 - cimetidine H2– antagonist;
1975 -verapamil- calciumantagonist and 1981 - captopril - antihypertensive.
There are some specific examples representing new therapeuticagent  eg. Metormine
glipizide-anti diabetic.
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(D) Latest Drug Developments
The current interest in the creation of large, searchable libraries of
organic compounds has captured the imagination of organic chemists and
the drug discovery community. In numerous laboratories the Efforts are focused
on the introduction of chemical diversity, which have been recently reviewed
and pharmacologically interesting compounds have been identified from li-
braries of widely different compositions.
Today, the chief source of agents for the cure, the mitigation or the
prevention of diseases are the organic compounds, natural or synthetic, to-
gether with so-called organometallics. Such agents have their origin in a num-
ber of ways (a) from naturally occurring materials - of both plant and animal
origin, and (b) from the isolation of organic compounds synthesized in labora-
tory whose structures are closely related to those of naturally occurring com-
pounds for eg. atropine, steroids, morphine, cocaine etc. that have been
known to possess useful medicinal properties.
The process of drug design is extensively driven by the instinct  and
experience of pharmaceutical research scientists. It is often instructive to at-
tempt to “capture” these experiences by analyzing the historical record that
are successful drug design projects of the past. From this analysis, the infer-
ences are drawn  which play an important role in shaping our  current and
future projects. Towards this region, we would like to analyse the structures of
a large number of drugs - the ultimate product of a successful drug design
effort. Our goal for this is to  begin to deconvolute this information in order to
apply it to design of new drugs.
Different kinds of drugs are developed for different types of diseases
viz. which can be defined with their names of the modern drugs are as under.
(a) Anticancer drugs
The drugs, which stops the abnormal growth of cell tissues in human
body, are termed as anticancer drug. Vinblastin and Busulphan are the novel
anticancer drugs.
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(b) Hepatoprotective drugs
Drugs, which gives vitality to liver and protects liver by giving immunity
power against antibodies, are termed as Hepatoprotective drug.
(c) Antimalarial drugs
Drugs, which kills the plasmodium causing malaria are called antima-
larial drug. Combination of Sulphamethoxazole with Pyrimethamine is a
novel antimalarial drug.
(d)      Drug for meningitis
Drugs, which cures the inflammation of meningitis, are termed as
meningitis drugs Cifalexin is a novel meningitis drug.
(e)      Drug for typhoid
Drugs, which kills the bacteria of Salmonella typhi causing typhoid are
known as typhoid drugs. A novel drug for typhoid is Ciprofloxacin.
(f)       Antidiabetic drugs
Drugs, which converts the excess glucose of blood into glycogen are
termed as antidiabetic drugs. Novel antidiabetic drugs are Metformin,
Glipizide and Gliclazide.
(g) Antitubercular drugs
Drugs, which kills the bacteria of mycobacterium tuberculosis and thus
cures lesions of pleural cavity. A novel antitubercular drug is Ethambutol.
(h) Antiasthamatic drugs
             Drugs, which prevents the attack of asthama and gives relax respira-
tion are called antiasthamatic drugs. Novel antiasthamatic drugs are
Ethophylline, Theophylline and Asmon.
(i) Antihypertensive drugs
            Drugs, which normalizes the blood pressure by dilating blood vessels
are called antihypertensive drugs. Novel antihypertensive drugs are
Atenolol,  Amlodipine and Nifedipine.
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(j)        Anti-AIDS drugs
          Drugs, which kills the viruses of AIDS i.e., HIV-1 and HIV-2 are called
anti-AIDS drugs. Novel drugs are Zidovudine, Acyclovir and Didanosine.
(k) Antacid drugs
           Drugs, which neutralize the acid in stomach and stops excessive
secretion of acid, are called antacid drugs. Novel antacid drugs are
Omeprazole and Lansoprazole.
(l)      Non steroidal antiinflammatory drugs (NSAID)
Drugs, which gives relief from fever, pain and inflammation are called
NSAID. Novel NSAID are Pyroxicam, Meloxicam and Nimesulide.
Different kind of drugs generally used are designed as anaesthetic,
ant i tuberculostat ic,  ant ihypertensive, ant iconvulsant,  anthelmint ic,
antiinflammatory, sedative and hypnotics which prompted us to synthesise
drugs having pyrazolo[3,4-d]pyrimidines, quinazolines and pyrazoles moi-
eties as a better therapeutic activity.
? Aims and objectives of the present investigation are
(a) To generate  severa l  b io log ica l ly  ac t ive  moie t ies  such as
pyrazolo[3,4-d]pyrimidines, quinazolines and pyrazoles.
(b) To characterize these products for their structural assignment using
various spectroscopic techniques like IR, PMR and Mass spectroscopy.
(c) To screen these new derivatives for their antimicrobial activity using
different s t ra ins  o f  bacter ia  and fung i  and to  compare ant imicrob ia l
act iv i ty  with
different known drugs at different concentrations for their MIC values.
In view of these facts, the research work presented in thesis are as
follows.
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( I )   STUDIES ON  PYRAZOLO [3,4-d] PYRIMIDINE
( II )   STUDIES ON PYRIMIDINE
( III )   STUDIES ON THIENO [3,2-c] PYRAZOLE
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   PART - I
STUDIES ON  PYRAZOLO [3,4-d] PYRIMIDINES
INTRODUCTION
Pyrazolo[3,4-d]pyrimidine (1) is a fused heterocyclic compound in
which pyrimidine with its “d” position is fused at 3 and 4 positions of pyrazole
ring. R. Justoni et al.,1 have synthesized 6-methyl-1,3-diphenyl-1H-pyrazolo-
[3,4-d] pyrimidine-4-(5H)-ones in 1938. Pyrazolo [3,4-d] pyrimidine ring is iso-
meric with the purine (2) ring and therefore, is of interest as a model for bio-
logically active compounds. Pyrazolo[3,4-d]pyrimidine is also known as
allopurine.
















(1)     (2)
Pyrazolo[3,4-d]pyrimidine  Purine ring system
There are two other possible isomers of pyrazolo[3,4-d]pyrimidines
(3,4), which are fused at different positions of pyrazole ring and are represented
as under.









       (3)       (4)
     Pyrazolo[3,2-f]-1,2,4-triazine Pyrazolo[4,3-d]pyrimidine
METHODS FOR SYNTHESIS OF PYRAZOLO[3,4-d]PYRIMIDINES
Extensive studies have been made in the field of synthesis of pyrazolo-
[3,4-d]  pyrimidines. Various methods for the synthesis of pyrazolo[3,4-d] pyri-
midines have been described as under:
(a) By the condensation of 5-Amino-4-cyano-pyrazole with 5-nitro-2-
furonitrile led to formation of 4-amino-6-(5’-nitro-2’-furyl)-1H-pyrazolo [3,4-d]
pyrimidines 2.
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(b) By the cyclocondensation of 4,6-Dichloro-5-formylpyrimidine with
hydrazine hydrate led to formation of 1H-pyrazolo [3,4-d] pyrimidines 3.
(c) By the fusion of 1,3-Dimethyl-6-hydrazino uracil at 150oC with dimethyl
formamide dimethylacetal (DMFDMA) led to formation of 2-alkyl-5,7-
dimethyl pyrazolo [3,4-d] pyrimidine-4,6(5H, 7H)-diones 4.
(d) By the fusion of 5-Arylazo-6-arylidene-hydrazino-1,3-dimethyl uracils
at 200oC led to formation of 2-benzyl-5,7-dimethyl-3-phenylpyrazolo [3,4-d]
pyrimidines-4,6(5H,7H)-diones 5.
(e) By the cyclocondensation of 5-Amino-4-cyano pyrazole with guanidine
carbonate led to formation of 4,6-diaminopyrazolo [3,4-d] pyrimidines6.
(f) By the cyclocondensation of Arylidene derivative of 1,3-diphenyl uracil
with hydrazine hydrate led to the formation of pyrazolo [3,4-d] pyrimidines7.
(g) By the cyclocondensation of 4-Carboxamido-5-amino-1,2,3-trihydropyrazole
with formamide led to the formation of pyrazolo[3,4-d]pyrimidines 8.
(h) By the cyclocondensation of 3,4-Dicyano-5-amino-1-N-substituted
pyrazole  with trichloro acetonitrile led to formation of pyrazolo [3,4-d] pyrim-
idines 9.
(i) By the cyclocondensation of 3-Aryl-2-arylamino-5-cyano-6-methyl-
sulphonylpyrimidine-4-one with hydrazine hydrate  led to formation of pyrazolo
[3,4-d] pyrimidines 10.
(j) By the cyclization of substituted 5-Amino-1H-pyrazole-4-carbonitrile with
formic acid or carbon disulphide or formamide or urea or thiourea or guani-
dine11.
(k) By the cyclization of substituted Ethyl-(4-cyano-1H-pyrazol-5-yl)
imidoformate with ammonium hydroxide or hydrazine hydrazide or acid hy-
drazide11.
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(l) By the cyclization of 2-Chloro-6-methoxy quinoline-3-carboxaldehyde





















































X = O/ S/ NH.
The present work is explained by considering basic mechanism of
multicomponents biginelli reaction. This includes the condensation of substi-
tuted benzaldehydes (a) with either urea or thiourea or guanidine to form
hemiaminal (b) with some similarities to the mannich condensation. Hemiaminal
(b) undergoes dehydration in presence of acid catalyst to produce iminium
cation (c) as a intermediate. The enamine (iminium cation) (c) generated acts
as an electrophile for the nucleophilic addition of keto enol of pyrazolone with
removal of proton to produce (d). The intermediate (d) undergoes intramo-
lecular condensation in presence of acid between oxygen of ketone and amino
group of urea or thiourea or guanidine to give the cyclised targeted product (e).




































































X = O / S / NH.
This mechanism includes the condensation of substituted benzaldehydes
(a) with keto enol of pyrazolone  (b) to form intermidiate (c) with some simi-
larities to the aldol condensation. Intermidiate (c) udergoes dehydration in pres-
ence of acid catalyst to produce arylidine (d). The condensation of arylidine
(d) with either urea or thiourea or guanidine to form hemiaminal intermidiate
(e). Hemiaminal intermidiate (e) undergoes intramolecular condensation in
presence of acid between oxygen of ketone and amino group of urea or thio-
urea or guanidine to give cyclised targeted product (f).
MEDICINAL IMPORTANCE OF PYRAZOLO [3,4-d] PYRIMIDINES
Considerable research has been undertaken to extend the activity and
reduce toxicity of Pyrazolo [3,4-d] pyrimidines. The specific biological activi-
ties of  Pyrazolo [3,4-d] pyrimidines have been represented as under.
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(a) Hyperglycemia 13,15 (b) Protozoacidal 16
(c) Hypoglycemia 17 (d) Antimalarial 20
(e) Anticancer 24,25,35,50 (f) Analgesic, antipyretic,
antiinflammatory 26,29,36,46
(g) Antimycotic agent 31 (h) Xanthine oxidase inhibitor 14,34
(i) Antitumor 30,38,47 (j) Anti HIV 40,44
(k) Anxiolytic agent 32 (l) Cardiovascular 23,49,51,53,54
(m) Antileishmanial 39,41,48 (n) Tranquilizer 52
(o) Blood sugar lowering agent 18 (p) Antiparasitic 21
(q) Antianaphylactic agent 22 (r) Coccidiostatic agent 27
(s) Anticonvulsant 42 (t) Antiviral 28,33,37,43,45
(u) Antiallergic 19 (v) Antimicrobial activity56
A.S. Bell et al.,55 have prepared pyrazolo[3,4-d]pyrimidines (05) which
are useful for treatment of memory enhancement, hypertension, congestive heart











M. L. Taha et al.,57 have synthesized pyrazolo[3,4-d]pyrimidine(06,07,08)
and were evaluated for their inhibitory effects against the replication of HIV-
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R.Riguera et al.,58 have synthesized 1,4 and 6 substituted 1H-pyrazolo
[3,4-d] pyrimidines (09,10,11) and their effect on the release of histamine from

































M. Friedman et al.,59 have prepared 3-(azo hetero)-aryl-1H-pyrazolo [3,4-













J. Markwalder et al.,60 have synthesized 6-substituted pyrazolo [3,4-d]
pyrimidin-4-ones (13) useful as cyclin dependent kinase (cdk) inhibitors for
treating cancer and proliferative diseases. M. M. Ghorab et al.,61 have syn-
thesized novel series of pyrazolo[3,4-d]pyrimidine (14) and evaluated for anti-
microbial activity comparable to antibiotic Chloramphenicol as standard anti-
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K.H.Yoo et al., 62 have prepared 1,4,6-trisubstituted pyrazolo [3,4-d]






















S.R.Shin et al.,63 have synthesized a series of pyrazolo [3,4-d] pyrim-
idines (17) which are evaluated in a plaque reduction assay. This class of
compounds provide remarkable evidence that they are very specific for hu-










B.S.Holla et al.,64 have synthesized pyarazolo[3,4-d]pyrimidine (18) as
antibacterial and antifungal properties. R. D. Hubbard et al.,65 have prepared
pyrazolo[3,4-d]pyrimidine (19) which are useful for kinase inhibitors possessed
moderate potency for insulin-like growth factor receptor (IGR-IR), a promising
target for cancer chemotherapy.





















Recently, R.Ducray et al.,66 have synthesized novel 4-anilino-1H-
pyrazolo[3,4-d]pyrimidine (20) and evaluated in vitro for erbB2 and epidermal
growth factor receptor (EGFR) kinase inhibition. Overexpression of EGFR and












PHARMACOLOGY OF RECENT DRUGS:
The most successful and well understood pyrazolo[3,4-d]pyrimidine com-
pound is acyclovir (21), which is highly active against herpes simplex virus
(HSV), varicella zoster virus infections and is used clinically.67,68 Acyclovir
is a 2’-deoxyguanosine analoge that contains an acyclic side chain in place of
the deoxyribose ring. It contains all of the atoms of 2’-deoxyguanosine, with
the exception of the 2’- and 3’-carbons and 3’-hydroxy group of the deoxyribose
ring.









Like most nucleoside analogues, acyclovir is a prodrug. Unlike other
necleoside analogs such as 3-Azido-3’deoxythymidine(AZT), however, prodrug
activation is one of the mechanisms by which acyclovir obtains selectivity. The
compound has a selectivity index of approximately 3000; the IC50 is 300mM
for inhibition of HSV-1, while the IC50 is 300mM for cytotoxicity to host Vero
cells in vitro.67 This selectivity is derived from two different mechanisms: Dif-
ferential activation of acyclovir in infected cells and increased potency against
HSV DNA polymerase. Acyclovir is phosphorylated 30-120 times faster with
extracts from HSV-1-infected cells compared to uninfected cell extracts.68
Moreover, the ki values for HSV-encoded DNA polymerases are 10-40 times
lower than for cellular DNA polymerases.67 Thus the active form of acyclovir
is present in greter quntities within virally infected cells and is also more po-
tent against viral DNA polymerase.
Activation of acyclovir to its triphosphate form is mediated by both viral
and cellular enzymes. Virally encoded thymidine kinase produces acyclovir
monophosphate, which is further phosphoryalated by cellular GMP kinase to
the diphosphate derivative. The diphosphate is converted to acyclovir triph-
osphate derivative by cellular kinases such as phosphoglycerate kinase. There
are several lines of evidence that supports HSV thymidine kinase as a key
enzyme for the antiviral effect of acyclovir.67 Perhaps the most convincing
evidence is derived from studies with thymidine kinase-deficient mutants of
HSV, which are resistant to acyclovir because no phosphorylation occurs within
infected cells.
The triphosphate form of acyclovir inhibits DNA polymerase. The mecha-
nism of inhibition is complex and may involve enzyme inactivation.69 Initially,
the compound competes with dGTP for binding to the polymerase-template
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complex. Following binding, it has been suggested that enzyme inactivation
occurs by the formation of a tight,irreversible enzyme-DNA-acyclovir triphos-
phate ternary complex. Addition of dGTP to this complex does not release
active viral DNA polymerase. Interestingly, DNA polymerase from the host cell is
not inactivated in this manner. In addition to dGTP complition and enzyme
inactivation,acyclovir triphosphate inactivates the viral DNA template by chain
termination, since it does not contain  3’-OH group necessary for the addition
of subsequent dNTPs.70 In virally infected cells, incomplete DNA replication
occurs upon treatment with acyclovir.71
Several analoges of acyclovir have been investigated, both at the
level of the target enzymes and for antiviral effect. Various alterations to
the aliphatic side chain of acyclovir are tolerated by the HSV thymidine ki-
nase, as long as the terminal hydroxy group is retained for phosphorylation72.
However, the enzyme is far less tolerant of modification to the heterocyclic
base moiety. Since the pyrimidines are the natural substrates for the viral thy-
midine kinase, it seems logical to predict that pyrimidine analogs of acyclovir
might be good kinase substrates and antiviral agents. However, this is not the
case. Similarly, among purine analogs, only those containing guanine are good
substrates for the viral  enzyme72.
Gaciclovir (22) is an acyclovir analogs that contains an additional
hydroxymethyl group in the side chain73. Because this compound contains
groups that mimic both, the 5’-OH and 3’-OH groups of deoxyguanosine, it
does not act as a chain terminator for DNA synthesis. Nevertheless, compound
(23) is selectively phosphorylated by the viral thymidine kinase and, as the
triphosphate form, inhibits Herpes Simplex virus-1(HSV-1, HSV-2) poly-
merase76. Gaciclovir has been reported to be superior to acyclovir against
human cytomegalovirus (HCMV). Although the compound is converted to the
triphosphate form in HCMV-infected cells, the enzymes responsible for this
transformation are not yet known. There is no evidence that HCMV encodes a
thymidine kinase.
Among acyclovir analogs, the cyclic monophosphate derivative has been
reported to have the broadest spectrum of activity against DNA viruses.68,75
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Within cells, compound (23) is converted to the (S) enantiomer of ganciclovir
monophosphate (24), the same compound that is obtained from phosphoryla-
tion of (22) by HSV-1 thymidine kinase. Other analogs that have been pre-
pared includes compound (25) and a series of related derivatives68,76. These
compounds have a similar mechanism as acyclovir, and several compounds






































(22)           (23)                (24)     (25)
In view of procuring highly potent biodynamic agents and after reviewing
literature survey on pyrazolo[3,4-d]pyrimidines for their various  pharmaco-
logical activities, synthesis of pyrazolo[3,4-d]pyrimidines have been under-
taken which can be summarized in the following section as under.
SECTION - I   : Preparation and biological evaluation of 3-Isopropyl-
-4-substituted phenyl-1,4,5,7-tetrahydro-6H-pyrazolo-
[3,4-d] pyrimidin-6-ones.
SECTION - II : Preparation and biological evaluation of 3-Isopropyl-
-4-substituted phenyl-1,4,5,7-tetrahydro-6H-pyrazolo-
[3,4-d] pyrimidine-6-thiones.
SECTION - III : Preparation and biological evaluation of 3-Isopropyl-
-4-substituted phenyl-1,4,5,7-tetrahydro-6H-pyrazolo-
[3,4-d] pyrimidin-6-imines.
SECTION - IV : Preparation and biological evaluation of 3-Isopropyl-
-4-substituted phenyl-1-phenyl-1,4,5,7-tetrahydro-
6H-pyrazolo [3,4-d] pyrimidin-6-ones.
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SECTION - V : Preparation and biological evaluation of 3-Isopropyl-
-4-substituted phenyl-1-phenyl-1,4,5,7-tetrahydro-
6H-pyrazolo [3,4-d] pyrimidine-6-thiones.
SECTION - VI : Preparation and biological evaluation of 3-Isopropyl-
4-substituted phenyl-1-phenyl-1,4,5,7-tetrahydro-
6H-pyrazolo [3,4-d] pyrimidin-6-imines.
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SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 3-ISOPROPYL-4-
SUBSTITUTED PHENYL-1,4,5,7-TETRAHYDRO-6H-PYRAZOLO [3,4-d]-
PYRIMIDIN-6-ONES.
Keeping in view of wide spectrum biodynamic activit ies13-56 o f
pyrazolo[3,4-d]pyrimidines and with a view to have potent therapeutic
agents, the synthesis of 3-Isopropyl-4-substituted phenyl-1,4,5,7-
tetrahydro-6H-pyrazolo[3,4-d]pyrimidin-6-ones (Ia-j) have been synthesized
by the condensation of different substituted aldehydes, 5-isopropyl-2,4-











R = Substituted Phenyl
The constitution of the products (Ia-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (Ia-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations  :
i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(Ia-j)  were compared with standard drugs viz. Amoxicillin, Chloramphenical,
Sparfloxacin, Levofloxacin, Griseofulvin and Fluconazole.






























    (Ia-j)
R = Substituted Phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-ISOPROPYL-4-
SUBSTITUTED PHENYL-1,4,5,7-TETRAHYDRO-6H-PYRAZOLO [3,4-d]
PYRIMIDIN-6-ONES.
(A) Preparation of 5-Isopropyl-2,4-dihydro-3H-pyrazol-3-one.
A Mixture of methyl-4-methyl-3-oxopentanoate (1.44 gm, 0.01 M), and
hydrazine hydrate (0.68 ml, 0.01 M) was stirred for 1 hrs at room temperature.
The product obtained was isolated and crystallized from methanol. Yield : 86
%, M.P. : 92 °C, (Required : C, 57.12%; H, 7.99%; N, 22.21% for C6H10N2O
Found : C, 57.05%; H, 7.90%; N, 22.15%).
TLC  solvent system  Rf1  :  Ethyl acetate : Hexane (3.5 : 6.5)         = 0.42.
TLC  solvent system  Rf2  :  Methanol         : Chloroform (1.0 : 9.0) = 0.59.
(B) P r e p a r a t i o n  o f  3- Isopropyl-4-(p -methoxyphenyl) -1,4,5,7-
tetrahydro-6H-pyrazolo [3,4-d] pyrimidin-6-ones. (Ij)
A mixture of 5-isopropyl-2,4-dihydro-3H-pyrazol-3-one (1.26 gm, 0.01M),
p-methoxy benzaldehyde (1.36 ml, 0.01 M), urea (0.90 gm, 0.015 M) and
catalytical amount of acid in ethanol(30 ml)  was heated under reflux condition
for 8-10 hrs. The reaction mixture was kept at room temperature for two hrs.
The yellow crystalline product obtained was isolated and recrystallized from
ethanol. Yield : 75%, M.P. : 245°C, (Required : C, 62.92%; H, 6.34%; N, 19.57%
for C15H18N4O2 Found : C, 62.84%; H, 6.28%; N, 19.51%).
TLC  solvent system  Rf1  :  Ethyl acetate : Hexane (3.5 : 6.5)         = 0.58.
TLC  solvent system  Rf2  :  Methanol         : Chloroform (1.0 : 9.0) = 0.77.
Similarly, other compounds (Ia-j) were synthesized. The physical data
are recorded in Table-I.
(C) Antimicrobial activity of 3-Methyl-4-aryl-6-mercaptomethyl-4,5-
dihydro-1H-pyrazolo [3,4-d] pyrimidines (Ia-j).
Antimicrobial activity testing was carried out by using cup-plate
method77, which has been described as under.
 * Antibacterial activity
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S. pyogens MTCC-442  S. aureus MTCC-96 and B. subtillis MTCC-
441 (Gram positive bacteria) were grown in nutrient broth and E. coli MTCC-
443  (Gram negative bacteria) in Peptone water (PW, 1% bacteriological pep-
tone and 0.5% Sodium chloride in water) for 24 hrs., this gave an optimum
growth of the test  bacteria. Each purified compound was dissolved in dim-
ethyl formamide (DMF) sterilized by filtration by using sintered glass filter and
stored at 4°C. Each agent was then added to molten nutrient agar in the fol-
lowing concentrations i.e. : 0 (control), 5, 25, 50, 100, 250 (μg/ml) and poured
into sterile petri dished. The pH of the medium was maintained at 7.2 -7.4.
The inoculum consisted of an overnight grown broth culture of a bacterium
diluted in such a manner that a 2 mm (internal diameter) loopful of the culture
contain 105 colony-forming unit (CFU). These were then spot inoculated on
nutrient  agar  plates containing increasing amount of a compound, incu-
bated at 37°C up to 24 hrs. The minimum inhibitory concentration78-79 (MIC)
values were recorded in form of zones of inhibition in m.m. for bacterias which
are recorded in Table No. Ia and Ib.
   * Antifungal activity
C. albicans MTCC-227 and A. niger MTCC-282 was employed for
testing antifungal activity using cup-plate method77. The culture was main-
tained on Sabouraud's agar for 72 hrs., this gave an optimum growth of the
test fungal spores. Each purified compound was dissolved in  dimethyl
formamide (DMF), sterilized by filtration by using sintered glass filter and
stored at 4°C. Each agent was then added to Sabouraud's agar in the follow-
ing concentrations i.e. : 0 (control), 5, 25, 50, 100, 250 (μg/ml) and poured
into sterile petri dished. The inoculum consisted of an overnight grown broth
culture of a bacterium diluted in such a manner  than a 2 mm (internal diam-
eter) loopful of the culture contain 105 colony-forming unit (CFU). These were
then spot inoculated on Sabouraud's agar plates containing increasing amount
of a compound, incubated at 37°C up to 48 hrs. The minimum inhibitory con-
centration78-79 (MIC) values were recorded in form of zones of inhibition in
m.m. for  fungii which are recorded in Table No. Ic.

































































































































































   




   































   




   































   




   































   




   






























   




   
































   




   
































   




   




























   





   




   































   




   

































   




   


















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)







IR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(m-CHLOROPHENYL)-



















* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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C-H (asym. def., m)
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C-H (sym. str., m)
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IR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-NITROPHENYL)-1,4,5,7-
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IR  SPECTRAL  STUDY  OF   3-ISOPROPYL4-(p-METHOXYPHENYL)-
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PMR  SPECTRAL  STUDY  OF  3-ISOPROPYL-4-(m-CHLOROPHENYL)-
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-CHLOROPHENYL)-
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-FLUOROPHENYL)-
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-NITROPHENYL)-
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-METHOXYPHENYL)-
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m/z = 44 (B.P.),
C3H8
m/z = 78 (M+1),
(Ib)













































































































































m/z = 248.5 (M+2),
m/z = 214 (M+1),
m/z = 158 (M+1),
m/z = 87 (M-2),
m/z = 114 (M-1),
m/z = 108
m/z = 128 (B.P.),
m/z = 78 (M+1),
m/z = 170.5 (M-1),m/z = 155.5 (M-2),






















































































































































m/z = 232 (M+1),
m/z = 214 (M+2),
m/z = 195,
m/z = 168,
m/z = 113 (M-2),
m/z = 274
m/z = 78 (M+1),
m/z = 106 (M-1),
m/z = 92,
m/z = 135 (B.P.),




















































































































































m/z = 214 (M+2),
m/z = 168,
m/z = 113 (M-2),
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m/z = 244 (B.P.),
m/z = 214 (M+1),
m/z = 113 (M-2),
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NH
NNH2
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NH
N
m/z = 158 (M+1),
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SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 3-ISOPROPYL-4-
SUBSTITUTED PHENYL-1,4,5,7-TETRAHYDRO-6H-PYRAZOLO [3,4-d]-
PYRIMIDIN-6-THIONES.
Keeping in view of wide spectrum biodynamic activit ies13-56 o f
pyrazolo[3,4-d]pyrimidines and with a view to have potent therapeutic
agents, the synthesis of 3-Isopropyl-4-substituted phenyl-1,4,5,7-
tetrahydro-6H-pyrazolo [3,4-d] pyrimidin-6-thiones (IIa-j) have been synthe-
sized by the condensation of substituted phenyl aldehydes, 5-isopropyl-











R = Substituted Phenyl
The constitution of the products (IIa-j) have been delineated by
elemental analyses, IR, PMR and Mass spectral data.
The products (IIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations  :
i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(IIa-j) were compared with standard drugs viz., Amoxicillin, Chloramphenical,
Sparfloxacin, Levofloxacin, Griseofulvin and Fluconazole.
























      (IIa-j)
 R = Substituted Phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-ISOPROPYL-4-
SUBSTITUTED PHENYL-1,4,5,7-TETRAHYDRO-6H-PYRAZOLO [3,4-d]-
PYRIMIDIN-6-THIONES. (IIa-j).
(A) Preparation of 5-Isopropyl-2,4-dihydro-3H-pyrazol-3-one.
For preparation, refer Part - I, Section - I, Page No. 31.
(B) P r e p a r a t i o n  o f  3- Isopropyl-4-(p -methoxyphenyl) -1,4,5,7-
tetrahydro-6H-pyrazolo [3,4-d] pyrimidin-6-thiones. (IIj)
A mixture of 5-isopropyl-2,4-dihydro-3H-pyrazol-3-one (1.26 gm, 0.01M),
p-methoxy benzaldehyde (1.36 ml, 0.01 M), thiourea (1.14 gm, 0.015 M) in
ethanol(30 ml) and catalytical amount of acid was heated under reflux condi-
tion for 8-10 hrs. The reaction mixture was kept at room temperature for two
hrs. The yellow crystalline product  obtained was isolated and recrystallized
from ethanol. Yield : 68%, M.P. : 274°C, (Required : C, 59.58%; H, 6.00%; N,
18.53% for C15H18N4O2 Found : C, 59.50%; H, 5.92%; N, 18.45%).
TLC  solvent system Rf1  :  Ethyl acetate : Hexane         (4.0 : 6.0) = 0.58.
TLC  solvent system Rf2   :  Methanol       : Chloroform (1.0 : 9.0) = 0.68.
Similarly, other compounds (IIa-j) were synthesized. The physical data
are recorded in Table-II.
(C) Antimicrobial activity of 3-Methyl-4aryl-6-methylsulfonyl-1H-pyrazolo
[3,4-d]pyrimidines (IIa-j).
Antimicrobial activity testing was carried out as described in part - I,
section - I, page No. 31. The MIC values of test solution are recorded in
Table No. IIa, IIb and IIc.
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C=N  (str., v)
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IR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-NITROPHENYL)-1,4,5,7-


















































6 5Par t  - I ,  S e c t i on  -  I I . . . ,  “ Studies on pyrazolo[3,4-d]pyrimidines.”











































































































































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)






Ph-O-C (sym. str., s)
C-H (def., v,s)
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(m-CHLOROPHENYL)-
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-CHLOROPHENYL)-
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PMR SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-FLUOROPHENYL)-
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL4-(p-NITROPHENYL)-
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL4-(p-METHOXYPHENYL)-
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m/z = 172 (M+1),
m/z = 158 (M+1),
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SECTION - III
PREPARATION AND BIOLOGICAL EVALUATION OF 3-ISOPROPYL-4-
SUBSTITUTED PHENYL-1,4,5,7-TETRAHYDRO-6H-PYRAZOLO [3,4-d]-
PYRIMIDIN-6-IMINES.
Keeping in view of wide spectrum biodynamic activit ies13-56 o f
pyrazolo[3,4-d]pyrimidines and with a view to have potent therapeutic
agents, the synthesis of 3-Isopropyl-4-substituted phenyl-1,4,5,7-
tetrahydro-6H-pyrazolo [3,4-d] pyrimidin-6-imines (IIIa-j) have been synthe-
sized by the condensation of different substituted aldehydes, 5-isopropyl-












R = Substituted Phenyl
The constitution of the products (IIIa-j) have been delineated by
elemental analyses, IR, PMR and Mass spectral data.
The products (IIIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations  : 0
(control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory  Con-
centration) values. The biological activities of the synthesized compounds
(IIIa-j) were compared with standard drugs viz., Amoxicillin, Chloramphenical,
Sparfloxacin, Levofloxacin, Griseofulvin and Fluconazole.

























R = Substituted Phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-ISOPROPYL-4-
SUBSTITUTED PHENYL-1,4,5,7-TETRAHYDRO-6H-PYRAZOLO [3,4-d]-
PYRIMIDIN-6-IMINES.
(A) Preparation of 5-Isopropyl-2,4-dihydro-3H-pyrazol-3-one.
For preparation, refer Part -I, Section - I, Page No.31
(B) Preparation of 3-Isopropyl-4-(p-methoxyphenyl)-1,4,5,7-tetra-
hydro-6H-pyrazolo [3,4-d] pyrimidin-6-imines. (IIIj)
A mixture of 5-isopropyl-2,4-dihydro-3H-pyrazol-3-one (1.26 gm, 0.01M),
p-methoxy benzaldehyde (1.36 ml, 0.01 M), guanidine hydrochloride (1.43 gm,
0.015 M) and add catalytical amount of acid in ethanol(30 ml) was heated
under reflux condition for 8-10 hrs. The reaction mixture was kept at room tem-
perature for two hrs. The yellow crystalline product  obtained was isolated and
recrystallized from ethanol. Yield : 53%, M.P. : 139°C, (Required : C, 63.14%;
H, 6.71%; N, 24.54% for C15H19N5O Found : C, 63.04%; H, 6.63%; N,
24.46%).
TLC  solvent system Rf1  : Ethyl acetate : Hexane        (4.0 : 6.0) = 0.53.
TLC  solvent system Rf2  : Methanol        : Chloroform (1.0 : 9.0) = 0.61.
Similarly, other compounds (IIIa-j) were synthesized. The physical data
are recorded in Table-III.
(C) Antimicrobial  activity of 3- Isopropyl-4-substitutedphenyl-
1,4,5,7-tetrahydro-6H-pyrazolo [3,4-d] pyrimidin-6-imines. (IIIa-j)
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 31. The MIC values of test solution are recorded in Table
No. IIIa, IIIb and IIIc.
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(m-CHLOROPHENYL)-
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-CHLOROPHENYL)-
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-FLUOROPHENYL)-
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-NITROPHENYL)-
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-METHOXYPHENYL)-


















































































































































































m/z = 228 (M-1),
m/z = 185,
m/z = 78 (M+1),





























m/z = 112.5 (M+1),
CH3
































































































































m/z = 226 (M+1),
































m/z = 115 (M+1),
m/z = 82,


























































































































































m/z = 202 (M-1),
m/z = 189,
m/z = 110 (M+1),m/z = 147,
m/z = 68 (M-1),
m/z = 132 (M-1),
m/z = 160 (M+1), m/z = 174,
m/z = 120,
C13H18N2





























































































































m/z = 172 (M+1), m/z = 198,
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m/z = 42 (M+2) (B.P.), (IIIh)











































































































m/z = 172 (M+1), m/z = 198,



























m/z = 78 (M+1),


















m/z = 44 (B.P.),
 C3H8
(IIIj)
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SECTION - IV
PREPARATION AND BIOLOGICAL EVALUATION OF 3-ISOPROPYL-4-
SUBSTITUTED PHENYL-1-PHENYL-1,4,5,7-TETRAHYDRO-6H-PYRAZOLO-
[3,4-d] PYRIMIDIN-6-ONES.
Keeping in view of wide spectrum biodynamic activit ies13-56 of
pyrazolo[3,4-d]pyrimidines and with a view to have potent therapeutic
agents, the synthesis of 3-Isopropyl-4-substituted phenyl-1-phenyl-1,4,5,7-
tetrahydro-6H-pyrazolo [3,4-d] pyrimidin-6-ones (IVa-j) have been synthe-
sized by the condensation of different substituted aldehydes, 5-isopropyl-










R = Substituted Phenyl
The constitution of the products (IVa-j) have been delineated by
elemental analyses, IR, PMR and Mass spectral data.
The products (IVa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations  :
i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(IVa-j) were compared with standard drugs viz. Amoxicillin, Chloramphenical,
Sparfloxacin, Levofloxacin, Griseofulvin and Fluconazole.




















            R = Substituted Phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-ISOPROPYL-4-
SUBSTITUTED PHENYL-1-PHENYL-1,4,5,7-TETRAHYDRO-6H-PYRAZOLO-
[3,4-d] PYRIMIDIN-6-ONES.
(A) Preparation of 5-Isopropyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one.
A Mixture of methyl-4-methyl-3-oxopentanoate (1.44 gm, 0.01 M), and
phenyl hydrazine (2.02 ml, 0.01 M) in methanol(10 ml) was heated under reflux
condition for 4 hrs and diethyl ether(10 ml) was added in to reaction mixture.
The reaction mixture was kept at room temperature for 10 hrs. The yellow crys-
talline product obtained was isolated and crystallized from ethanol. Yield : 72
%, M.P. : 114 °C, (Required : C, 71.26%; H, 6.98%; N, 13.85% for C12H14N2O
Found : C, 71.15%; H, 6.91%; N, 13.78%).
TLC  solvent system Rf1   : Ethyl acetate  : Hexane (2.0 : 8.0) = 0.49.
TLC  solvent system Rf2    :  Methanol       : Toluene (1.0 : 9.0) = 0.67.
(B) Preparation of 3-Isopropyl-4-(4-methoxyphenyl)-1-phenyl-1,4,5,7-
tetrahydro-6H-pyrazolo [3,4-d] pyrimidin-6-one. (IVj)
A mixture of  5-isopropyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (1.26
gm, 0.01M), p-methoxy benzaldehyde (1.36 ml, 0.01 M), and urea (0.90 gm,
0.015 M) catalytical amount of acid in ethanol(30 ml) was heated under reflux
condition for 8-10 hrs. The reaction  mixture was kept at room temperature for
two hrs. The yellow crystalline product  obtained was isolated and crystallized
from ethanol. Yield : 52%, M.P. : 147°C, (Required : C, 72.39%; H, 6.94%; N,
16.08% for C21H22N4O2 Found : C, 72.30%; H, 6.85%; N, 16.01%).
TLC  solvent system Rf1   : Ethyl acetate  : Hexane  (2.0 : 8.0) = 0.66.
TLC  solvent system Rf2    :  Methanol       : Toluene (1.0 : 9.0) = 0.48.
Similarly, other compounds (IVa-j) were synthesized. The physical data
are recorded in Table-IV.
(C) Antimicrobial activity of 3-Isopropyl-4-substituted phenyl-1-phenyl
-1,4,5,7-tetrahydro-6H-pyrazolo [3,4-d] pyrimidin-6-ones. (IVa-j).
Antimicrobial activity testing was carried out as described in part - I,
section - I, page No. 31. The MIC values of test solution are recorded in
Table No. IVa, IVb and IVc.
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PMR  SPECTRAL  STUDY  OF 3-ISOPROPYL-1-PHENYL-4- (m-CHLOROPHENYL)-
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PMR  SPECTRAL STUDY OF 3-ISOPROPYL-4-(p-CHLOROPHENYL)-1-
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PMR  SPECTRAL  STUDY  OF  3-ISOPROPYL-4- (p-FLUOROPHENYL)-1-PHENYL-
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PMR  SPECTRAL  STUDY  OF 3-ISOPROPYL-4- (p-NITROPHENYL)-1-PHENYL-
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PMR  SPECTRAL  STUDY  OF  3-ISOPROPYL-4-(p-METHOXYPHENYL)-1-PHENYL-
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PMR  SPECTRAL  STUDY  OF 3-ISOPROPYL-4- (p-NITROPHENYL)-1-PHENYL-



























































































































































































































m/z = 288 (M+1),
m/z = 266,
m/z = 226 (M+1),
m/z = 92 (M+1),
m/z = 254 (M+1),
m/z = 186 (M+1),
m/z = 198 (M+1),m/z = 128,
m/z = 108 (M+2),
m/z = 212 (M+1),








 C5H12N4 C11H8N4O C11H10N4
C10H10N4
m/z = 78 (M+1) (B.P.),
C6H6
(IVb)























































































































m/z = 92 (M+2),
m/z = 196 (M+1),















m/z = 236.5 (M+1),
m/z = 208.5 (M+1),
m/z = 156,





















































































































































































m/z = 256 (M-1) (B.P.),
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SECTION - V
PREPARATION AND BIOLOGICAL EVALUATION OF 3-ISOPROPYL-4-
SUBSTITUTED PHENYL-1-PHENYL-1,4,5,7-TETRAHYDRO-6H-PYRAZOLO-
[3,4-d] PYRIMIDIN-6-THIONES.
Keeping in view of wide spectrum biodynamic activit ies13-56 of
pyrazolo[3,4-d]pyrimidines and with a view to have potent therapeutic
agents, the synthesis of 3-Isopropyl-4-substituted phenyl-1-phenyl-1,4,5,7-
tetrahydro-6H-pyrazolo[3,4-d]pyrimidin-6-thiones (Va-j) have been synthe-
sized by the condensation of different substituted aldehydes, 5-isopropyl-










R = Substituted Phenyl
The constitution of the products (Va-j) have been delineated by
elemental analyses, IR, PMR and Mass spectral data.
The products (Va-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations  :
i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(Va-j) were compared with standard drugs viz., Amoxicillin, Chloramphenical,
Sparfloxacin, Levofloxacin, Griseofulvin and Fluconazole.























    R = Substituted Phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-ISOPROPYL-4-
SUBSTITUTED PHENYL-1-PHENYL-1,4,5,7-TETRAHYDRO-6H-PYRAZOLO-
[3,4-d] PYRIMIDIN-6-THIONES.
(A) Preparation of 5-Isopropyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-
one.
For preparation, refer Part - I, sec - IV, Page No. 113.
(B) Preparation of 3-Isopropyl-4-(p-methoxyphenyl)-1-phenyl-1,4,5,7-
tetrahydro-6H-pyrazolo [3,4-d] pyrimidin-6-thiones. (Vj)
A mixture of  5-isopropyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (2.02
gm, 0.01M), p-methoxy benzaldehyde (1.36 ml, 0.01 M), thiourea (1.14 gm,
0.015 M) and add catalytical amount of acid in ethanol(30 ml) was heated
under reflux condition for 8-10 hrs. The reaction mixture was kept at room tem-
perature for two hrs. The yellow crystalline product  obtained was isolated and
recrystallized from ethanol. Yield : 57%, M.P. : 178°C,  (Required : C, 66.64%;
H, 5.86%; N, 14.80% for C21H22N4OS Found : C, 66.55%; H, 5.78%; N,
14.80%).
TLC  solvent system Rf1 : Ethyl acetate : Hexane        (2.5 : 7.5) = 0.46.
TLC  solvent system Rf2 :  Methanol       : Chloroform (1.0 : 9.0) = 0.59.
Similarly, other compounds (Va-j) were synthesized. The physical data
are recorded in Table - V.
(C) Antimicrobial activity of 3-Isopropyl-4-substituted phenyl-1-phenyl
-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-d]pyrimidin-6-thiones (Va-j).
Antimicrobial activity testing was carried out as described in part - I,
section - I, page No. 31. The MIC values of test solution are recorded in
Table No. Va, Vb and Vc.
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(m-CHLOROPHENYL)-1-
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PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-FLUOROPHENYL)-
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C19H15N5O2S
C17H17N5O2S
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SECTION - VI
PREPARATION AND BIOLOGICAL EVALUATION OF 3-ISOPROPYL-4-
SUBSTITUTED PHENYL-1-PHENYL-1,4,5,7-TETRAHYDRO-6H-PYRAZOLO-
[3,4-d] PYRIMIDIN-6-IMINES.
Keeping in view of wide spectrum biodynamic activit ies13-56 o f
pyrazolo[3,4-d]pyrimidines and with a view to have potent therapeutic
agents, the synthesis of 3-Isopropyl-4-substituted phenyl-1-phenyl-1,4,5,7-
tetrahydro-6H-pyrazolo[3,4-d] pyrimidin-6-imines (VIa-j) have been synthe-
sized by the condensation of different substituted aldehydes, 5-isopropyl-











R = Substituted Phenyl
The constitution of the products (VIa-j) have been delineated by
elemental analyses, IR, PMR and Mass spectral data.
The products (VIa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations  : 0
(control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory Con-
centration) values. The biological activities of the synthesized compounds
(VIa-j) were compared with standard drugs viz.,Amoxicillin, Chloramphenical,
Sparfloxacin, Levofloxacin, Griseofulvin and Fluconazole.























R = Substituted Phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-ISOPROPYL-4-
SUBSTITUTED PHENYL-1-PHENYL-1,4,5,7-TETRAHYDRO-6H-PYRAZOLO-
[3,4-d] PYRIMIDIN-6-IMINES.
(A) Preparation of 5-Isopropyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-
one.
For preparation, refer Part - I, sec - IV, Page No. 113.
(B) Preparation of 3-Isopropyl-4-(p-methoxyphenyl)-1-phenyl-1,4,5,7-
tetrahydro-6H-pyrazolo [3,4-d] pyrimidin-6-imines. (VIj)
A mixture of  5-isopropyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (2.02
gm, 0.01M), p-methoxy benzaldehyde (1.36 ml, 0.01 M), guanidine hydrochlo-
ride (1.43 gm, 0.015 M) and catalytical amount of acid in ethanol(30 ml) was
heated under reflux condition for 8-10 hrs. The reaction mixture was kept at
room temperature for two hrs. The yellow crystalline product  obtained was
isolated and recrystallized from ethanol. Yield : 53%, M.P. : 91°C,  (Required :
C, 69.78%; H, 6.41%; N, 19.38% for C21H22N4OS Found : C, 69.69%; H,
6.33%; N, 19.30%).
TLC  solvent system Rf1 : Ethyl acetate : Hexane       (2.0 : 8.0) = 0.56.
TLC  solvent system Rf2 : Methanol       : Chloroform (0.5 : 9.5) = 0.64.
Similarly, other compounds (VIa-j) were synthesized. The physical data
are recorded in Table-VI.
(C) Antimicrobial activity of 3-Isopropyl-4-substituted phenyl-1-phenyl
-1,4,5,7-tetrahydro-6H-pyrazolo [3,4-d] pyrimidin-6-imines (VIa-j).
Antimicrobial activity testing was carried out as described in part - I,
section - I, page No. 31. The MIC values of test solution are recorded in
Table No. VIa, VIb and VIc.
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PMR SPECTRAL  STUDY  OF   3-ISOPROPYL-4- (m-CHLOROPHENYL)-1-
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PMR  SPECTRAL  STUDY  OF   3- ISOPROPYL-4- (p-CHLOROPHENYL)-1-
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PMR  SPECTRAL  STUDY  OF   3- ISOPROPYL-4-(p-FLUOROPHENYL)-1-



































































178Par t  - I ,  S e c t i on  -  VI . . . ,  “ Studies on pyrazolo[3,4-d]pyrimidines.”
PMR  SPECTRAL  STUDY  OF   3-ISOPROPYL-4-(p-NITROPHENYL)-1-
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PMR  SPECTRAL  STUDY  OF   3- ISOPROPYL4-(p-METHOXYPHENYL)-1-





















































































































































































































































































































































































































































































m/z = 44 (B.P.),
C3H8
(VIc)
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m/z = 218 (M-1),
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Pyrimidine (26) is a six membered heterocyclic compound consisting





Generally pyrimidine derivatives such as 2-hydroxy-substituted-pyrimidine,
2-mercapto-substituted-pyrimidine and 2-amino-substituted-pyrimidine are
studied. Pyrimidines have been isolated from the nucleic acid hydrolysates.
Pyrimidines are among those molecules that make life possible, have
been some of the building blocks of DNA and RNA. Several analogues of
pyrimidines have been used as compounds that interfere with the synthesis
and functioning of nucleic acids e.g. fluorouracil, which has been used in can-
cer treatment. Also there are some thiouracil derivatives, which produce ad-
verse reduction in susceptible patients and found more potent and less likely
to produce side effects and is being widely used85. There are several other
important groups of pyrimidines with medicinal uses.
Pyrimidine ring carrying various substituents may be built up from two
or three aliphatic fragments by the principle synthesis or by a variety of other
syntheses, which are complimentary rather than alternative to it. An alternative
method of synthesis is the isomerisation or break down of another hetero-
cycles such as    hydration of purine, but such methods are rarely used. Pyrimi-
dine is best  considered as a resonance hybrid to which the uncharged equiva-
lent Kekule structures  18 and 18a and charged structures 18b and 18g con-
tributes. The self consistent π (pi) electron densities required for the ground
state of pyrimidine are 0.776, 0.825 and 1.103 for positions 2, 4 and 5 respec-
tively90. Despite considerable localization of π (pi) electrons at nitrogen atoms
of pyrimidines the ring system is still sufficiently aromatic to possess substan-
tial stability. This has a great advantage in the primary synthesis of pyrim-
idines.























The first primary synthesis from aliphatic fragments was carried out by
Frankland et.al., in 1848. Since then a many distinct primary synthetic meth-
ods have been devised79,81-84,87,89,92,94,95,98.  It is also possible to pre-
pare pyrimidines from other heterocyclic compounds such as pyrrole80, imi-
dazole82, isoxazole and oxazole86,88, pyridine96, pyrazine97, 1,3,5-triaz-
ine91, oxazine93, thiazine99 by different processes.
SYNTHETIC METHODS FOR PYRIMIDINES
Various methods for synthesis of pyrimidines  which are reported in the
literature are as follows.
(a) By the condensation of urea and malonic acid led to formation of pyrimidine102.
(b) By the condensation of malonic ester and urea led to formation of pyrimidine103.
(c) By the condensation of formamidine with phenylazomalononitrile led to
formation of 4,5,6-triaminopyrimidine101.
(d) By the condensation of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of pyrimidines100.
(e) By the condensation of thiourea and substituted ß-ketoester in pres
ence of sodium ethoxide led to formation of 2-mercaptopyrimidines104.
(f) By the condensation of chalcones with dicyandiamide in presence of
piperidine led to formation of pyrimidines105.
(g) By thermal or microwave irridiation of thiourea and substituted ß-ketoester
in presence of dimethylformamide led to formation of substituted
tetrahydropyrimidines106.
(h) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of substi tuted
dihydro pyrimidin-2-ones catalysed by CuCl2107.
(i) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
Par t  -  I I ,  In t roduc t i on . . . ,  “ Studies on pyrimidines.” 200
ß-ketoester with urea or thiourea led to formation of 3,4-dihydro
pyrimidin-2-(1H)-ones/thiones under microwave irradiation108.
(j) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester  wi th  urea or  th iourea led to  format ion of  d ihydro
pyrimidin-2-(1H)- ones catalysed by Tin (II) chloride (SnCl2)108.
(k) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of  3,4-dihydro
pyrimidin-2-(1H)-ones by microwave induced eco-friendly solvent free


















































X = O, S & NH.
The present work is explained by considering basic mechanism of
multicomponents biginelli reaction. This includes the condensation of substi-
tuted benzaldehydes (a) with either urea or thiourea or guanidine to form
hemiaminal (b) with some similarities to the mannich condensation. Hemiaminal
(b) undergoes dehydration in presence of acid catalyst to produce iminium
cation (c) as a intermediate. The enamine (iminium cation) (c) generated acts
as an electrophile for the nucleophilic addition of keto enol of 4-methyl-oxo-N-
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phenylpentanamide with removal of proton to produce (d). The intermediate
(d) undergoes intramolecular condensation in presence of acid between oxy-
gen of ketone and amino group of urea or thiourea or guanidine to give the

































































X = O, S & NH.
This mechanism includes the condensation of substituted benzaldehydes
(a) with keto enol of 4-methyl-3-oxo-N-phenylpentanamide (b) to form
intermidiate (c) with some similarities to the aldol condensation. Intermidiate
(c) udergoes dehydration in presence of acid catalyst to produce arylidine
(d). The condensation of arylidine (d) with either urea or thiourea or guanidine
to form hemiaminal intermidiate (e). Hemiaminal intermidiate (e) undergoes
intramolecular condensation in presence of acid between oxygen of ketone
and amino group of urea or thiourea or guanidine to give cyclised targeted
product (f).
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PHARMACOLOGICAL IMPORTANCE OF PYRIMIDINES
Numerous pyrimidines are well known drugs for variety of diseases. They
may be placed in four categories viz. barbiturates, sulfonamides, antimicrobi-
als and antitumor agents. Uracil, thymine, alloxan, vicine and divicine, cytosine,
chroticacid, willardiline, tetradotoxine, becimethrian (28), blasticidine (29),























(28)          (29)         (30)
Pyrimidine derivatives have wide varieties of usages. Pyrimidine ring
system is also present in Vitamin B2 and folic acid. Pyrimidine ring system
having a mercapto group occupy a unique position in medicinal chemistry.126
These types of derivatives play a vital role in biological processes112-114 as
well as synthetic drugs.111
Some of the therapeutic activities of pyrimidine derivatives can be
summarized as follows.
(a) Antithyroid124,125 (b)      Antitumor117,146-147
(c)      Antihypertensive127,138-139  (d)      Antiinflammatory1137,173-174
(e)      Diuretic116 (f)       Antimalarial118,120,123
(g)      Antispasmodic119 (h)      Anticonvulsant148
(i)       Antineoplastic128,166 (j)       Anthelmintic132
(k)      Antimicrobial115,129-133,140,149-172
(l)       Cardiovascular141-143 (m)     Antiviral134,163-166
(n)      Platelet aggregation inhibitor121,122
(o)      Antihistamine135,136 (p)      Anti-HIV144,175
(q) Antitubercular145
The basis of any rational drug discovery programme is fundamently, the
Medicinal Chemistry. Although the synthesis of modified nucleic acids has been
a subject of interest for some time, the intense focus on the medicinal chemis-
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try of oligonucleotides dates perhaps to not more than five years. As a result
of this, the scope of medicinal chemistry has recently been expanded enor-
mously, but the biological data of supporting the conclusions about synthetic
strategies have just begun to emerge.
Modifications in the base, sugar and phosphate moeities of oligonucle-
otides and oligonucleotide conjugates have been reported. The subjects of
medicinal chemical programmes include approaches to create enhanced af-
finity and more selective  affinity for RNA or duplex structures, the ability to
cleave nucleic acid targets, enhanced nuclease stability, cellularuptake and
distribution, in vivo tissue distribution, metabolism and clearance. Although
substantial progress in the    medicinal chemistry of oligonucleotides has been
made in the past three years, it is not yet possible to reach the conclusion
about the therapeutic ability of the novel modifications. Preliminary data on
effects on nuclease stability and hybridization properties for a few modifica-
tions and activity in vitro suggest that the next generation of oligonucleotides
may display substantially improved potencies and   selectivity.
PYRIMIDINE MODIFICATIONS (Nucleotide)
A relatively large number of modified pyrimidines have been synthe-
sized and now incorporated into oligonucleotides and evaluated. The principle
sites of modification are C-2, C-4, C-5 and C-6 (31) .  These and other













sites of pyrimidine Modification
(31)
In as much as the C2 position is involved in Watson-Crick hybridization,
oligonucleotides containing C2 alkyl modified  pyrimidines have shown unattrac-
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tive hybridization characters. However, an oligonucleotide containing 2-thioth-
ymidine (32) was found to hybridize well to DNA and, in fact even better to
RNA with a thermal melting temperature (ΔTm) value of 1.5°C/modification. In
a different study, oligoribonucleotides with 2’-o-methyl-2-thiouridine (33) ex-
hibited a thermal melting temperature (ΔTm) value of +5.5°C/modification
when hybridized against RNA resulting from a highlly preoganized RNA-like
C3’-endo conformation (attributed to the combination of 2-thio modification
and 2’-o-Mesubstituent). Oligonucleotides with this modification also exhibit
better hybridization discrimination for the wobble uracil-guanosine (U-G) base
pair formation compared to the normal uracil-adenine (U-A) base pair. This
selectivity is a result of weaker    hydrogen bonding and increased steric bulk
























In contrast, the pyrimidine modifications in 4-position with interesting
properties have been reported. 4-Thiopyrimidines (34,35) have been incorpo-
rated in to o l igonucleot ides wi th  no s ign i f icant  negat ive ef fect  on
hybridization.However,    recent studies have shown destabilization in the nor-
mal uracil-adenine (U-A) base pair formation and stabilization of the wobble
uracil-guanosine (U-G) base pair for 4-thiouridine. A bicyclic and an 4-methoxy
analog of cytosine were shown to hybridize with both purine bases in DNA with
thermal melting temperature (Tm) values approximately equal to that of natu-
ral base pairs.  Additionally, a fluorescent base has been incorporated into
oligonucleotides and shown to enhance DNA-DNA duplex stability.200






















(34)          (35)
The pyrimidine modification at C5 position including halogenated
nucleosides have been reported. Although the stability of duplexes may be
enhanced by incorporation 5-halogenated uracil containing nucleosides, the
occasional mispairing with guanidine and the potential that the oligonucleotide
might degrade and release toxic nucleosides analogs cause concern. Oligo-
nucleotides containing 5-propynylpyrimidine (36,37,38) modification have been
shown to enhance the duplex stability thermal melting temperature (ΔTm = 1.6°C/
modification ), and support RNase H activity. The 5-heteroaryl-pyrimidines were
also shown to increase the stability of duplexes. A more dramatic influence was
reported for the tricyclic 2’-deoxycytidine analoges, termed phenoxazine, ex-
hibiting an enhancement of  2-5°C/modification, depending on the positioning
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As expected, modifications in the C6 position of pyrimidines are highly
dupled destabilizing. Oligonucleotides containing 6-azapyrimidines (39) have
been shown not only to reduce the  thermal melting temperature (Tm) value by
1-2°C per modification, but also to enhance the nuclease stability of oligonucle-















The increasing interest in the early 1970s in properties and use of inter-
feron (IFN) together with the difficulty in producing useful amounts of interferon
(IFN) led to the search for agents that would induce IFN in the host.
Precedenced at that time for interferon (IFN) inducers included viruses and bacte-
rial wall constituents and entities of large molecular weight such as the poly-
nucleotides. There were also several examples of low molecular weight substances
such as certain antibiotics and the antiviral agent, tilorone.185 In 1976 it was re-
ported that 6-methyl pyrimidinone(2-amino-5-bromo-6-methyl-4-(3H)pyrimidinone,
ABMP) induced circulating levels of interferon (IFN) in several animal specis upon
oral or intraperitoneal administration.180 Subsequent structure-activity studies
yielded a more potent and less toxic 6-phenyl ananlog called ABPP or bropirimine
(2-amino-5-bromo-6-phenyl-4-(3H)pyrimidinone) (figure 1 and Table 1).178,184
Bropirimine and related 6-aryl analogs were examined extensively for efficacy
in virus and tumor models, along with their immunomodulatory properties and
overall pharmacological effects.190


















 Figure 1 : Preliminary SAR of antiviral activity of pyrimidinones
    Table - I
Antiviral Activity
monosubstituted Disubstituted       Heterocyclic
Active         2-F,OMe, Me 3,5-OMe 1-Naphthyl
          3-F,OMe, Cl, NO2 2,5-Cl2 2-Pyrazyl
Me, CF3, MeCH2CH2O, 3,5-OMe 2,3-pyridyl
Br,I 3,4-Cl2 2-Furyl
4-F, Cl 3,5-Cl2
Inactive 4-Me, CN, Butyl, 2,3-OMe 2-Napthyl
OH,OCH2ph, OMe 1-Furyl
4-Pyridyl
                                         2-Quinoline
As with the polynucleotides, the pyrimidinones exhibited significant ac-
tivity against interferon (IFN) sensitive viruses such as Semliki Forest virus in vivo.
However, in addition, they exhibited prophylactic and therapeutic activity upon
either local or systemic administration to rodents infected with a variety of
DNA viruses, such as the herpes viruses (HSV-1, HSV-2 , CMV  and pseudora-
bies), and when administered intranasally for upper respiratory infections, such
as infectious    bovine rhinortacheites, influenza A and para-influenza-3. Par-
ticularly interestion activity was noted  with bropirimine on intravaginal admin-
istration in protection against HSV-2 intravaginal infection in guinea pigs, an
important model for genital herpes in humans.191 Bropirimine also exhibited
activity when given either intraperitoneally or orally to mice infected with Listera
monocytogenes. The efficacy in this model  was not abrogated by the addition
of anti-interferon (IFN)  antibody.186
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PYRIMIDINES AS ANTITUMOUR AGENTS
A number of other pyrimidine antagonists displaying antitumour activ-
ity, in which the base is conjugated to a modified suger ring have been re-
ported. Although D-Arabinofuranosyl uridine (ara-uridine) shows no useful
acitivity,  and 5-bromo- and 5-iodo-D-arabinofuranosyl uridine inhibit the growth
of  sarcoma 180 and L1210 cells in culture.177 Other thymidine analogues with
simi lar  act iv i ty  i n c l u d e  5 - a z i d o m e t h y l - , 5 - a m i n o m e t h y l  a n d  5 -
hydroxymethyl-2’-deoxyu-ridine179. 3’-Amino-3’-deoxy thymidine181 and 3’-
amino-2’,3’-dideoxycy-tidine182 also posses strong activity against L1210 leu-
kaemia 2’-Deoxy-2’-fluoro-5-methyl-1-B-D-arabinofuranosyluracil (FMAU; 40)
is highly active against arabinofuranosyl cytidine (ara-C) resistant L1210 and P815
cell lines both in vitro and in vivo.188 2-B-D-Ribofuranosylthiazole-4-
carboxamide (Tiazofurin; 41) has aroused much interest recently for its activ-
ity against solid tumour such as lung carcinoma. It is metabolized to an ana-
logue of NAD in which the thiazole-4-carboxamide moiety replaces the nicoti-
namide ring. However, it also depresses the synthesis of DNA and RNA, and
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PYRIMIDINES AS ANTI-HIV AGENTS
The strategy of designing nucleoside analogs that are selective for vi-
ral DNA polymerases is the most well-studied and successful approch to
viral chemotherapy, and has led to the discovery of several clinically useful
antiviral drugs. This strategy, however, has inherent limitations. Human DNA
polymerases also required dNTP’s and the chemical mechanisms of polymer-
ization by the viral and human enzymes are similar. Nucleoside analogs often
Par t  -  I I ,  In t roduc t i on . . . ,  “ Studies on pyrimidines.” 209
have significant host toxicity that is probably related to inhibition of host cell DNA
synthesis. Nevertheless, these compounds constitute the major class of antivi-
ral drugs, and this approach is likely to yield additional active compounds in
the near future. For the long term, however, other strategies may ultimately lead
tonmmore selective agent withn lower toxicity.
Obviously, the key to design analogue with a lower affinity for the host en-
zyme than the viral enzyme, which requires that there be structural differences
between the enzyme active sites. For reverse transcriptase, the most well stud-
ied inhibitor is 3’-azido-3’-deoxythymidine (AZT; 42), which is currently used










3’-azido-3’-deoxythymidine (AZT) inhibits HIV reverse transcriptase with
an IC50 of 40nM193, but is 100-300 times less active against mammalian
DNA polymerase α and DNA polymerase γ. The reason for this selectivity is
not clear since 3’-azido-3’-deoxythymidine (AZT) is a chain terminator for mam-
malian DNA polymerases and inhibits normal cellular DNA synthesis.183 Sev-
eral other dideoxynucleoside analogs have been shown to be potent inhibi-
tors of HIV replication in vitro.194,198 In general, these compounds have the same
mechanism of action as 3’-azido-3’-deoxythymidine (AZT), that is, intracellular
conversion to the triposphate derivative and subsquent inhibition of HIV re-
verse transcriptase.
Some of these compounds are simply analogs of the nautral 2’-deoxy-
nucleoside in which the 3’-OH group has been replaced with a hydrogen, such
as 2’,3’-dideoxycytidine(43), 2’,3’-dideoxyadenosine(44) and 2’,3’-dideo-
xythymidine (45). Other analogs contain a 2’-3’ double bond, such as 2’3’-
didehydro-2’,3’-dideoxythymidine (46). Several related analogs with other
modifications to the ribose ring or the heterocyclic base moiety have also been
reported to have activity against HIV or HIV reverse transcriptase.195,196
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R. A. Nugent et. al.,203 have synthesized pyrimidine thioethers (47)













A family of trisubstituted pyrimidines has been described as selective
COX-2 inhibitors. To explore the usefulness of pyrimidine derivatives as potential
NSAIDs. Aurelio Orjales et. al.,204 have synthesized novel pyrimidine deriva-
tives (48) and (49).
In vitro biological evaluation of these compounds has provided infor-
mation to determine the structural features necessary for COX-2 inhibitory ac-
tivity.












(48) Y = CH; X, Z = N      (49)  Y, Z = N; X = CH
F. Manetti et. al.,205 have synthesized novel pyrimidines (50) with





R = Ph, Me, CO2Me,     
       CONMe2, CONEt2
(50)
D.Rot i l i  e t  a l . ,206  have synthes ized 6-subst i tu ted- [1- (2 ,6-
difluorophenyl]pyrimidinones (51,52) and tested against endogenous,
nontelomeric reverse transcriptase (endo-RT) in human differentiating cell


















R. Stoorer et al.,207 have synthesized 3-substituted-6-(3-ethyl-4-
methylanilino)uracils (53,54) screened for their capacity to inhibit the replica-
tion-specific bacterial DNA plymerase IIIC (pol IIIC) and the growth of Gram+
bacteria in culture.



















(53)   n = 2,3,4. (54) n = 2,3,4.0
A.Or ja les  e t  a l . ,208  have synthes ized new ser ies  o f  2- (4-
methylsulfonylphenyl)and 2-(4-sulfamoylphenyl)pyrimidines (55) and evaluated









Recently, Y.Miyazaki et al.,209 have synthesized 4-amino-5,6-furo [2,3-d]









In view of procuring highly potent biodynamic agents and after review-
ing recent literature survey on oxo / thioxo / iminopyrimidines for their  various
methods of synthesis and different pharmacological activities, synthesis of py-
rimidines have been undertaken which can be summarized in the following
sections as follows:
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SECTION  - I : PREPARATION AND BIOLOGICAL EVALUATION OF 6-ISO-
PROPYL-N-SUBSTITUTED PHENYL-2-OXO-4-SUBSTI-
TUTED PHENYL-1,2,3,4-TETRAHYDROPYRIMIDINES.
SECTION  - II : PREPARATION AND BIOLOGICAL EVALUATION OF 6-ISO-
PROPYL-N-SUBSTITUTED PHENYL-2-THIOXO-4-SUB-
STITUTED PHENYL-1,2,3,4-TETRAHYDROPYRIMIDINES.
SECTION  - III : PREPARATION AND BIOLOGICAL EVALUATION OF 2-
IMINO-6-ISOPROPYL-N-SUBSTITUTED PHENYL-4-SUB-
STITUTED PHENYL-1,2,3,4-TETRAHYDROPYRIMIDINES.
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SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 6-ISOPROPYL-5-[-
N-(SUBSTITUTED PHENYL)]-CARBOXAMIDO-2-OXO-4-ARYL-1,2,3,4-
TETRAHYDRO PYRIMIDINES.
Keeping in view of wide spectrum biodynamic activit ies116-174
of pyrimidines and with a view to have potent therapeutic agents, the synthe-
sis of 6-Isopropyl-5-[N-(substituted phenyl)]-carboxamide-2-oxo-4-aryl-
1,2,3,4-tetra hydropyrimidines (VIIa-j) have been synthesized by the conden-
sation of different substituted aldehydes, 4-methyl-N-substituted phenyl-











   R,  R1=Substituted Phenyl
The constitution of the products (VIIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (VIIa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442, S. aureus
MTCC-96 and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-
443 and  (Gram negative) bacterial strain and antifungal activity towards
Aspergillus niger  MTCC-282 and Candida albicans MTCC-227 at differ-
ent concentrations  : i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC
(Minimum Inhibitory  Concentration) values. The biological activities of the syn-
thesized compounds (VIIa-j) were compared with standard drugs viz.,
Amoxicillin, Chloramphenical, Sparfloxacin, Levofloxacin, Griseofulvin
and Fluconazole.























R, R1= Substituted Phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 6-ISOPROPYL-5-[-
N-(SUBSTITUTED PHENYL)]-CARBOXAMIDO-2-OXO-4-ARYL-1,2,3,4-
TETRAHYDRO PYRIMIDINES.
(A) Preparation of 4-Methyl-3-oxo-N-[m-(trifluoromethyl)phenyl]
pentanamide.
For preparation, see reference no.210,211.
Yield : 71%, M.P. : 94°C, (Required : C, 57.14 %; H, 6.16 %; N, 5.13 %;
for C13H14NO2, Found : C, 57.04 %; H, 5.08 %; N, 5.04 %).
TLC  solvent system Rf1  :  Ethyl acetate : Hexane         (3.0 : 7.0) = 0.58.
TLC  solvent system Rf2   :  Methanol        : Chloroform (0.5 : 9.5)  = 0.62.
Similarly, other compounds were synthesized.
(B) Preparation of 6-Isopropyl-5-[N-[m- ( tr i f luoromethyl)phenyl] -
carboxamido-2-oxo-4-(m-chlorophenyl)-1,2,3,4-tetrahydropyrimidine (VIIa).
A mixture of 4-Methyl-3-oxo-N-[3-(trifluoromethyl)phenyl] pentanamide
(2.73 gm, 0.01M), 3-chlorobenzaldehyde (1.36 ml, 0.01 M), urea (0.90 gm,
0.015 M) and catalytical amount of conc. acid in ethanol(30 ml)  was heated
under reflux condition for 8-10 hrs. The reaction mixture was kept at room tem-
perature for 24 hrs. The yellow crystalline product obtained was isolated and
recrystallized from ethanol. Yield : 53 %, M.P. : 218°C, (Required : C, 57.61%;
H, 4.37%; N, 9.60% for C21H19N3O2ClF3 Found : C, 57.54%; H, 4.26%; N,
9.51%).
TLC  solvent system Rf1  :  Ethyl acetate : Hexane        (3.0 : 7.0)  = 0.51.
TLC  solvent system Rf2   :  Methanol        : Chloroform (0.5 : 9.5)  = 0.73.
Similarly, other compounds (VIIa-j) were synthesized. The physical data
are recorded in Table-VII.
(B) Antimicrobial activity of 6-Isopropyl-5-[-N-(substituted phenyl)]-
carboxamido-2- oxo-4-aryl-1,2,3,4-tetrahydro pyrimidines.(VIIa-j)
Antimicrobial activity testing was carried out as described in part - I,
section - I, page No. 31. The MIC values of test solution are recorded in
Table No. VIIa, VIIb and VIIc.
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)









IR  SPECTRAL  STUDY  OF 6-ISOPROPYL-5- [N-(3,4-DICHLOROPHENYL)]-
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)











IR  SPECTRAL STUDY OF  6-ISOPROPYL-5-[N-(3,4-DICHLOROPHENYL)]-
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)








C-NO2 (asym. str., s)
C-NO2 (sym. str., s)
C-H (def., v,s)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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PMR SPECTRAL STUDY OF 6-ISOPROPYL-5-[N-(3,4-DICHLOROPHENYL)]-
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C10H9ClN2O  C15H16F3N3O2 C18H13ClF3N3O2
(VIIa)




























































































































































































































































































































































































m/z = 162 (M+2),

























































































































































































m/z = 198 (M+2),
m/z = 78 (M+1),
































m/z = 44 (M+1) (B.P.),
C3H8
(VIIh)















































































































































































































m/z = 114 (M+1),
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SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 6-ISOPROPYL-5-[N-
(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-2-THIOXO-4-ARYL-1,2,3,4-
TETRAHYDROPYRIMIDINES.
Keeping in view of wide spectrum biodynamic activit ies116-174
of pyrimidines and with a view to have potent therapeutic agents, the synthe-
sis of 6-Isopropyl-N-substituted phenyl-2-thioxo-4-aryl-1,2,3,4-tetra hy-
dro pyrimidine-5-carboxamides (VIIIa-j) have been synthesized by the con-
densation of different substituted aldehydes, 4-methyl-N-substituted phe-












     R,  R1=Substituted Phenyl
The constitution of the products (VIIIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (VIIIa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations  :
i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(VIIIa-j) were compared wi th  s tandard drugs v iz . ,  Amoxici l l in ,
Chloramphenical,  Sparfloxacin, Levofloxacin, Griseofulvin and
Fluconazole.

























             R,  R1 = Substituted Phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 6-ISOPROPYL-5-[N-
SUBSTITUTEDPHENYL]-CARBOXAMIDO-2-THIOXO-4-ARYL-1,2,3,4-
TETRAHYDROPYRIMIDINES.
(A) Preparation of 4-Methyl-3-oxo-N-[3-(trifluoromethyl)phenyl]-
pentanamide.
For preparation, refer Part - II, Section - I, Page No.216
(B) Preparation of 6-Isopropyl-5-[N-(m-(trifluoromethyl)phenyl)]-
carboxamido-2-thioxo-4-(m-chlorophenyl)-1,2,3,4-tetrahydropyrimidine
(VIIIa)
A mixture of 4-Methyl-3-oxo-N-[3-(trifluoromethyl)phenyl] pentanamide
(2.73 gm, 0.01M), 3-chlorobenzaldehyde (1.40 ml, 0.01 M), thiurea (1.14 gm,
0.015 M) and catalytical amount of conc. acid in ethanol(30 ml)  was heated
under reflux condition for 8 to 10 hrs. The reaction mixture was kept at room
temperature for 24 hrs. The yellow crystalline product obtained was isolated
and recrystallized from ethanol. Yield : 56 %, M.P. : 232°C, (Required : C,
57.61%; H, 4.37%; N, 9.60% for C21H19N3O2SClF3 Found : C, 57.54%; H,
4.26%; N, 9.51%).
TLC  solvent system Rf1   :  Ethyl acetate : Hexane         (4.0 : 6.0) = 0.57.
TLC  solvent system Rf2   :  Methanol        : Chloroform  (1.0 : 9.0) = 0.63.
Similarly, other compounds (VIIIa-j) were synthesized. The physical data
are recorded in Table-VIII.
(B) Antimicrobial activity of 6-Isopropyl-5-[N-(substitutedphenyl)]-
carboxamido-2-thioxo-4-aryl-1,2,3,4-tetrahydro pyrimidines.(VIIIa-j)
Antimicrobial activity testing was carried out as described in Part-I,
Section - I, page No. 31. The MIC values of test solution are recorded in
Table No. VIIIa, VIIIb and VIIIc.
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S H J -2 0















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)













































Part  -  II . ,Se c t i on  -  II . . . ,  “  S tud i e s  on  py r imid ine s . ” 246
5 0 07 5 01 0 0 01 2 5 01 5 0 01 7 5 02 0 0 02 5 0 03 0 0 03 5 0 04 0 0 0









































































































S H J -2 2















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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S H J -4 1

















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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S H J -4 4
















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)








C-NO2 (asym. str., s)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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m/z = 219 (M-1),
NH
S
m/z = 151 (M+1),

























































































































































































































































































































































m/z = 369 (M-1),















































































m/z = 108 (M+1)(B.P.),
C6H8N2
(VIIIh)


























































































































































m/z = 290 (M+1),
















































Part  -  II . ,Se c t i on  -  II . . . ,  “  S tud i e s  on  py r imid ine s . ” 266
   
   
   











   
   
   
   
   
   
   
   
   





















    
    

































































































































































































































































































































































   
   
   
   
















































































































   
   
   
   










































































































































































    






































































































































































































































   
   
   
   
















































































































   
   
   
   


































































   
   
   
   









   
   
   
   
   
   
   
   
   
   
   
   


































































































































































































































































































































































































   
   
   
   





























































































































   
   
   
   
   
   












   
   
   
   
   
   
   
   
   



















    
































   
   
   
   



























































































































































































































Part  -  II ,  Sec t i on  -  III . . . ,  “  S tud i e s  on  Pyr imid ine s . ” 269
SECTION - III
PREPARATION AND BIOLOGICAL EVALUATION OF 2-IMINO-6-ISOPRO-
PYL-5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-4-ARYL-1,2,3,4-
TETRAHYDROPYRIMIDINES.
Keeping in view of wide spectrum biodynamic activit ies116-174
of pyrimidines and with a view to have potent therapeutic agents, the synthe-
sis of 2-Imino-6-Isopropyl-N-substituted phenyl-4-aryl-1,2,3,4-tetra
hydropyrimidine-5-carboxamides (IXa-j) have been synthesized by the con-
densation of different substituted aldehydes, 4-methyl-N-substituted phe-
nyl-3-oxopentanamides and guanidine hydrochloride in the presence of











    R,  R1=Substituted Phenyl
The constitution of the products (IXa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (IXa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations  :
i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(IXa-j)  were compared wi th  s tandard drugs v iz . ,  Amoxici l l in ,
Chloramphenical,  Sparfloxacin, Levofloxacin, Griseofulvin and
Fluconazole.
























        (IXa-j)
R,  R1 = Substituted Phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-IMINO-6-ISOPRO-
PYL-5-[N-(SUBSTITUTED PHENYL)]-CARBOXAMIDO-4-ARYL-1,2,3,4-
TETRAHYDROPYRIMIDINES.
(A) Preparation of 4-Methyl-3-oxo-N-[3-(trif luoromethyl)phenyl]
pentanamide.
For preparation, refer Part - II, Section - I, Page No.216
(B) Preparation of 2-Imino-6-isopropyl-[N-(3-(trifluoromethyl) phe-
nyl)]-carboxamido-4-(3-chlorophenyl)-1,2,3,4-tetrahydropyrimidine (IXa).
A mixture of 4-Methyl-3-oxo-N-[3-(trifluoromethyl)phenyl] pentanamide
(2.73 gm, 0.01M), 3-chlorobenzaldehyde (1.40 ml, 0.01 M), guanidine hydro-
chloride (1.43 gm, 0.015 M) and catalytical amount of conc. acid in ethanol(30
ml)  was heated under reflux condition for 8 to10 hrs. The reaction mixture was
kept at room temperature for 24 hrs. The yellow crystalline product obtained
was isolated and recrystallized from ethanol. Yield : 49 %, M.P. : 167°C, (Re-
quired : C, 56.78%; H, 5.16%; N, 8.28% for C21H20N4OClF3 Found : C, 56.65
%; H, 5.03 %; N, 8.16 %).
TLC  solvent system Rf1   :  Ethyl acetate : Hexane        (4.0 : 6.0) = 0.48.
TLC  solvent system Rf2   :  Methanol        : Chloroform (1.0 : 9.0) = 0.57.
Similarly, other compounds (IXa-j) were synthesized. The physical data
are recorded in Table-IX.
(B) Antimicrobial activity of 2-Imino-6-Isopropyl-5-[N-(substituted
phenyl)]-carboxamido-4-aryl-1,2,3,4-tetrahydropyrimidines.(IXa-j)
Antimicrobial activity testing was carried out as described in Part - I,
Section - I, page No. 31. The MIC values of test solution are recorded in
Table No. IXa, IXb and IXc.
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)






C-NO2 (asym. str., s)
C-NO2 (sym. str., s)
C-H (def., v,s)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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m/z = 150 (B.P.),
C9H14N2
(IXa)































































































































































































































C14H17N5O3 C13H18N4O2 C18H15ClN4O3 
(IXf)



































































































































m/z = 382 (M+1),

































































































































































































































m/z = 108 (M+1),












































m/z = 236 (M-1) (B.P.),
C12H16N2O3
(IXj)
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PART - III
STUDIES ON THIENO [3,2-c] PYRAZOLES
INTRODUTION :
Thieno[3,2-c]pyrazole (1) is a fused heterocyclic compound in which
pyrazole with its “c” position is fused at 3,2-position of thiophene ring. First of
all I. Y. Kvitko et al.,211 was synthesized 3-methyl-1-phenyl-5-thieno[2,3-c]
pyrazolecarboxylic acid by treatment of 5-chloro-3-methyl-1-phenyl-4-
pyrazolaldehyde with thioglycolic acid.There are two possible isomers of
thienopyrazole (57,58), which are fused at different positions of thiophene ring










   (57)     (58)
The chemistry of thieno [3,2-c] pyrazole was reviewed by I. Y. Kvitko in
1969. Different methods are available in literature for the preparation of
thieno[3,2-c]pyrazole.
METHODS FOR SYNTHESIS OF THIENO[3,2-c]PYRAZOLES :
Extensive studies have been made in the field of synthesis of thieno [3,2-c]
pyrazole. Various methods for the synthesis of thieno [3,2-c] pyrazole have been
described as under:
(1) By the reaction of 5-chloro-3-methyl-1-phenyl-4-pyrazolaldehyde with
thioglycolic acid.211
(2) By the reaction of 4-dimethylaminomethylene-3-methyl-1-phenyl-5-
thiopyrazolone with chloro acetic acid.212
(3) By the reaction of 5-chloro-3-methyl-1-phenyl-4-cyanopyrazole with N-
phenylthioacetamide.213
(4) By the reaction of dithiodipyrazolaldehyde with nitromethane.214
(5) By the reaction of methyl-4-pyrazoleacetate with carbon disulfide and
iodomethane.215































































































The present work is considering basic mechanism of multicomponents
geward reaction. This includes the condensation of malanonitrile (a) and
pyrazolone (b) to form arylidine (c) with some similarities to the knowvenagel
condensat ion. Aryl id ine (c)  react wi th sulpher (S8)  undergoes the
heterocyclization to form intermediate (d). Intermediate (d) undergoes
tutomerization in the presence of base to form the targeted product (e).
P a r t  -  I I I ,  I n t r o d u c t i o n . . . ,  “ Studies on thieno[2,3-c]pyrazole.” 300
THERAPEUTIC IMPORTANCE :
pyrazole derivatives are associated with diverse biological activities viz.,
(a) Anticancer234 (b) Antitumor232
(c) Antipyretic activity216 (d) Antiallergic227,230
(e) Local anaesthetic activity217 (f) Antiasthmatic224,227
(g) Antimicrobial activity228,231 (h) Antiviral233
(i) Antidiabetic activity235 (j) Tranquilizing activity218
(k) Fungicidal activity225 (m) Hypoglycemic activity219
(n) Diuretic activity221 (o) Anticonvulsant activity220
(p) Analgesic activity226 (q) Cardiovascular activity222
(r) Antibacterial236 (s) Antiinflammatory227,231
(t) Antihypertensive223
Thiophene derivatives are associated with diverse biological activities
viz.,
(a) Antimicrobial activity243,245 (b) Antiinflammatory246
(c) Analgesic activity246 (d) Ulcerogenic246
(e) Antideressant247
MEDICINAL INTEREST :
M.M.F.Ismail et al.,237 have prepared [1-(2,3,4,9-Tetrahydrocarba- zol-
1-yl)-2-phenyl-1-[(3-methyl-1-phenyl)pyrazol-5-one-1-ylidine]ethane (59) and the










      (59)
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Ki-Jun Hwang et al.,238 have synthesised compound (60) which   ex-













A. Ejima et al.,239 have prepared 3-[4-(3-Chlorophenyl)-1-piperazinyl]-
1-[5-methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-1-trans-propane (61) and evaluated
by assays of growth inhibition against several tumor cell lines in vitro as well
as antitumor activity against some tumor models when dosed both intraperito-









K. D. Kee et al.,240 have prepared compound (62) and evaluated for
their biological activity, which showed the highest Phospho- diesterage type-
5 (PDE5) inhibitory activity and comparable to better selectivity over PDE isoen-











P.J.Scammells et al.,241 have prepared 2-amino-3-aroylthiophenes
(63,64)  are agonist allosteric enhancers (AE) at the A1 adenosine receptor
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(A1AR), and syntheses of three kinds of novel 2-aminothiophenes and assays









I.M.Abdou et al.,242 have prepared 1,2-Dihydropyrazole glucosides and
tested for their antitumor activity. Gucoside (65) shows an in vitro IC50 value
















M. Dobosz et al.,243 have synthesized 4-Substituted-3-(thiophene-2-









C.R.Prokopp et al.,244 have synthesized pyrazolyl-thiazole derivatives
(68) and investigates the antinociceptive effect in mice.







S.A. Haroutounian et al.,245 have prepared tetrasubstituted pyrazole
derivatives (69) bearing a nitro substituent on their A-phenol ring were synthe-









After carringout literature survey, it was evident that sevral researcher
had tried to fused either benz or benznapthalo with thiophene ring and thiophene
ring is also fused with sevral heterocycles like pyrimidine, triazole and pyrazole
pyrimidine. Which exhibited potent antimicrobial,246,248 moderately potent
TGase inhibitors247, antiinflammatory249, analgesic249, antiulcerogenic249
and antidepressant250 activities.
During our research program it was found that pyrazolopyrimidine which
is known as sudopurine. In our research programm an attemp has been fo-
cused to replace pyrimidine from pyrazolopyrimidine and introduction of
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thiophene nucleus may lead to compounds of potent biological acivity.
Not much research work was focused on this type of heterocycles. The
new thienopyrazole derivatives have been synthesised which have been de-
scribed as under:
SECTION - I: Preparation and biological evaluation of 5-Substituted-
benzoyl-3-Methyl-1-phenyl-1,5-dihydropyrazolo-
[3’,4’:4,5] thieno [2,3-c] pyrazol-7-amines.
SECTION - II: Preparation and biological evaluation of 3-Methyl-
6-substitutedphenyl-1,5,6,7-tetrahydro-8H-pyrazolo-
[3’,4’:4,5] thieno [2,3-d] pyrimidin-8-ones.
SECTION - III: Preparation and biological evaluation of 3,6-Dimethyl-
6 - s u b s t i t u t e d  p h e n y l - 1 , 5 , 6 , 7 - t e t r a h y d r o - 8 H -
pyrazolo [3’,4’:4,5] thieno [2,3-d] pyrimidin-8-ones.
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SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 5-SUBSTITUTED
BENZOYL-3-METHYL-1-PHENYL-1,5-DIHYDROPYRAZOLO [3',4':4,5]
THIENO [2,3-c] PYRAZOL-7-AMINES.
Looking to the biodynamic activities216-236 of thienopyrazoles and
in order to have highly potent therapeutic agents, the synthesis of 5-Substi-
tuted benzoyl-3-methyl-1-phenyl-1,5-dihydro pyrazolo [3',4':4,5] thieno
[2,3-c] pyrazol-7-amines. (Xa-j) have been undertaken by  the condensation
of 5-amino-3-methyl-1-phenyl-1H-thieno [3,2-c] pyrazole-6-carbonitrile











                R =Substituted  Phenyl
The constitution of the products (Xa-j) have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (Xa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations  :
i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(Xa-j) were compared with standard drugs viz., Amoxicillin, Chloramphenical,
Sparfloxacin, Levofloxacin, Griseofulvin and Fluconazole.





















R = Substituted Phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 5-SUBSTITUTED
BENZOYL-3-METHYL-1-PHENYL-1,5-DIHYDROPYRAZOLO [3',4':4,5]
THIENO [2,3-c] PYRAZOL-7-AMINES.
(A) Preparation of 5-Amino-3-methyl-1-phenyl-1H-thieno [3,2-c ]
pyrazole-6-carbonitrile.
For Preparation, refer reference no.251,252.
Yield : 58%, M.P. : 126°C, (Required : C, 61.40%; H, 3.96%; N, 22.03%
for C13H10N4S, Found : C, 61.31%; H, 3.86% ; N, 21.96%).
TLC  solvent system Rf1 : Methanol : Dichloromethane (2.0 : 8.0) = 0.48.
TLC  solvent system Rf2 : Methanol : Chloroform           (1.0 : 9.0) = 0.52.
(C) Preparation of 5-(p-Methoxybenzoyl)-3-methyl-1-phenyl-1,5-
dihydropyrazolo [3',4':4,5] thieno [2,3-c] pyrazol-7-amine.
A mixture of  3-Methyl-5-amino-6-cyano-1H-thieno[3,2-c]pyrazole (1.78 gm,
0.01M), 4-methoxybenzohydrazide(1.66gm, 0.01M) in gla. aceticacid (40 ml)
was reflux for 6 hrs. The reaction mixture was poured into ice cold water. The
product obtained was filtered, dried and recrystallized from ethanol. Yield :
51%, M.P. : 138°C, (Required : C, 62.52%; H, 4.25%; N, 17.36% for
C21H17N5O2S, Found : C, 62.41%; H, 4.17% ; N, 17.25%).
TLC  solvent system Rf1: Methanol : Dichloromethane (2.0 : 8.0) = 0.59.
TLC  solvent system Rf2 : Methanol : Chloroform               (1.0 : 9.0) = 0.68.
Similarly, other compounds (Xa-j) were synthesized. The physical data
are recorded in Table No. X.
(D) Antimicrobial activity of  5-Substituted benzoyl-3-methyl-1-phenyl
-1,5-dihydropyrazolo [3',4':4,5] thieno [2,3-c] pyrazol-7-amines. (Xa-j).
Antimicrobial activity testing was carried out as described in part - I,
section - I, page No. 31. The MIC values of test solution are recorded in
Table No. Xa, Xb and Xc.
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IR  SPECTRAL  STUDY  OF   5-(p-CHLOROBENZOYL)-3-METHYL-1-










































Type  Vibration  mode
C-H (asym. str., m s)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)
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IR  SPECTRAL  STUDY  OF   5-(p-NITROBENZOYL)- 3-METHYL-1-PHE-


































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)





C-NO2 (asym. str., s)
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IR  SPECTRAL  STUDY  OF   5- (2,4-DICHLOROBENZOYL)-3-METHYL-1-

































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)
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IR  SPECTRAL  STUDY  OF   5-(p-METHYLBENZOYL)-3-METHYL-1-































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)





































IR  SPECTRAL  STUDY  OF   5- (p-METHOXYBENZOYL)-3-METHYL-1-
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PMR  SPECTRAL  STUDY  OF   5-(p-CHLOROBENZOYL)-3-METHYL-1-
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(Xf)
PMR  SPECTRAL  STUDY  OF   5-(p-NITROBENZOYL)-3-METHYL-1-








































































PMR  SPECTRAL  STUDY  OF   5-(2,4-DICHLOROBENZOYL)-3-METHYL-




























































PMR  SPECTRAL  STUDY  OF   3-METHYL-5-(p-METHYLBENZOYL)-1-
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(Xi)
PMR  SPECTRAL  STUDY  OF   5-(p-METHOXYBENZOYL)-3-METHYL-


















































































































































































m/z = 358 (M+1),




































































m/z = 43 (B.P.),
C2H5N(Xd)





















































































































































































































































































































































































































































































m/z = 358 (M+1),

















































m/z = 255 (M-1),
NH
N




















































































































































































m/z = 44 (B.P.),
CH4N2
(Xi)
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X b X c X d X
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X b X d X h
X b X c X
j
X b X d
X b X d X h
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X b X c X d X
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SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-6-(4-
SUBSTITUTED PHENYL)-1-PHENYL-1,5,6,7-TETRAHYDRO-8H-PYRAZ-
OLO [3',4':4,5]THIENO[2,3-d] PYRIMIDIN-8-ONE.
Looking to the biodynamic activities216-236  of thienopyrazoles and
in order to have highly potent therapeutic agents, the synthesis of 3-methyl-6-
(4-substitutedphenyl)-1-phenyl-1,5,6,7-tetrahydro-8H-pyrazolo [3',4':4,5]
thieno [2,3-d] pyrimidin-8-one (XIa-j)  have been undertaken by the
cyclocondensation of 5-amino-3-methyl-1-phenyl-1H-thieno [3,2-c]
pyrazole-6-carbonitrile and different substituted aromatic aldehydes in the pres-











R = Substituted Phenyl
The constitution of the products (XIa-j) have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (Xa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96
and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations  :
i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(Xa-j) were compared with standard drugs viz., Amoxicillin, Chloramphenical,
Sparfloxacin, Levofloxacin, Griseofulvin and Fluconazole.





















R = Substituted Phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-6-
SUBSTITUTEDPHENYL-1-PHENYL-1,5,6,7-TETRAHYDROPYRAZOLO
[3’,4’:4,5] THIENO [2,3-d] PYRIMIDIN-8-ONES.
(B) Preparation of 5-Amino-3-methyl-1-phenyl-1H-thieno[3,2-c ]
pyrazole-6-carbonitrile.
For preparation, See part - III, Section - I, Page no.307.
(C) Preparation of 3-Methyl-6-(p-methoxyphenyl)-1-phenyl-1,5,6,7-
tetrahydro-8H-pyrazolo[3',4':4,5]thieno[2,3-d]pyrimidin-8-one (XIj).
A mixture of 3-Methyl-5-amino-6-carboxamido-1H-thieno[3,2-c] pyrazole
(1.96 gm, 0.01M), 4-methoxybenzaldehyde(1.36gm, 0.01M) and con. sulphuric
acid (05ml) in gl. aceticacid (20ml) was reflux for 6 hrs. The reaction mixture
was poured into ice cold water. The product obtained was filtered, dried and
recrystallized from ethanol. Yield : 68%, M.P. : 137°C, (Required : C, 64.60%;
H, 4.65%; N, 14.35% for C21H18N4O2S, Found : C, 64.52%; H, 4.54% ; N,
14.25%).
TLC  solvent system Rf1 : Methanol : Chloroform           (0.5 : 9.5) = 0.52.
TLC  solvent system Rf2 : Methanol : Dichloromethane (1.0 : 9.0) = 0.59.
Similarly, other compounds (XIa-j) were synthesized. The physical data
are recorded in Table No. XI.
(D) Antimicrobial activity of 3-Methyl-6-substitutedphenyl-1-phenyl-
1,5,6,7-tetrahydro-8H-pyrazolo[3',4':4,5]thieno[2,3-d]pyrimidin-8-
ones(XIa-j).
Antimicrobial activity testing was carried out as described in part - I,
section - I, page No. 31.The MIC values of test solution are recorded in  Table
No. XIa, XIb and XIc.
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)




































IR  SPECTRAL  STUDY  OF   3-METHYL-6- (p-CHLOROPHENYL)-1-PHE-
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)



































IR  SPECTRAL STUDY OF 3-METHYL-6-(p-FLUOROPHENYL)-1-PHENYL-
1,5,6,7-TETRAHYDRO-8H-PYRAZOLO [3’ ,4’:4,5]  THIENO [2,3-d]-
PYRIMIDIN-8-ONE (XIe).
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)




































IR  SPECTRAL STUDY OF 3-METHYL-6-(p-NITROPHENYL)-1-PHENYL-
1,5,6,7-TETRAHYDRO-8H-PYRAZOLO [3’,4’:4,5] THIENO [2,3-d] PYRIM-
IDIN-8-ONE (XIg).
(XIg)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
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C=C & C-C (str., v)
C-H (o.o.p. def., m)
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C-O-C (asym. str., s)





























IR  SPECTRAL  STUDY  OF   3-METHYL-6-(p-METHOXYPHENYL)-1-
PHENYL-1,5,6,7-TETRAHYDRO- 8H-PYRAZOLO [3’,4’:4,5] THIENO [2,3-d]-
PYRIMIDIN-8-ONE (XIj).









































PMR  SPECTRAL  STUDY  OF   3-METHYL-6-(p-CHLOROPHENYL)-1-
































































PMR SPECTRAL  STUDY  OF   3-METHYL-6-(p-FLUOROPHENYL)-1-
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(XIg)
PMR SPECTRAL  STUDY  OF   3-METHYL-6- (p-NITROPHENYL)-1-PHE-
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(XIj)
PMR  SPECTRAL  STUDY  OF   3-METHYL-6-(p-METHOXYPHENYL)-1-





























































































































































































































































m/z = 44 (B.P.),
CH4N2
(XIc)
































































































































m/z = 245 (M-1),



































































































































































































































































































































































































































































































































































































m/z = 188 (M-1),













m/z = 44 (B.P.),
CH4N2
(XIc)
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SECTION - III
PREPARATION AND BIOLOGICAL EVALUATION OF 3,6-DIMETHYL-6-
S U B S T I T U T E D P H E N Y L - 1 - P H E N Y L - 1 , 5 , 6 , 7 - T E T R A H Y D R O - 8 H -
PYRAZOLO- [3',4':4,5] THIENO [2,3-d] PYRIMIDIN-8-ONES(XIIa-j).
Looking to the biodynamic activities216-236of thienopyrazoles and
in order to have highly potent therapeutic agents, the synthesis of 3,6-dim-
ethyl-1-phenyl-6-substituted phenyl-1,5,6,7-tetrahydro-8H-pyrazolo
[3',4':4,5] thieno [2,3-d] pyrimidin-8-ones. (XIIa-j) have been undertaken
by the cycloconden- sation of 5-amino-3-methyl-1-phenyl-1H-thieno [3,2-c]
pyrazole-6-carbonitrile and different substituted aromatic acetophenone in











     (XIIa-j)
            R=Substituted phenyl
The constitution of the products (XIIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (XIIa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations  :
i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(XIIa-j)  were compared wi th  s tandard drugs v iz . ,  Amoxici l l in ,
Chloramphenical,  Sparfloxacin, Levofloxacin, Griseofulvin and
Fluconazole.























R = Substituted Phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3,6-DIMETHYL-6-
SUBSTITUTEDPHENYL-1-PHENYL-1,5,6,7-TETRAHYDRO-8H-PYRAZOLO
[3',4':4,5] THIENO [2,3-d] PYRIMIDIN-8-ONES.
(B) Preparation of 5-Amino-3-methyl-1-phenyl-1H- thieno[3,2-c ]
pyrazole-6-carbonitrile.
For preparation, See part - III, Section - I, Page no. 307.
(C) Preparation of 3,6-Dimethyl-6-(p-methoxyphenyl)-1-phenyl-1,5,6,7-
tetrahydro-8H-pyrazolo [3',4':4,5] thieno [2,3-d] pyrimidin-8-one (XIj).
A mixture of 3-Methyl-5-amino-6-carboxamido-1H-thieno [3,2-c] pyrazole
(1.96 gm, 0.01M), 4-methoxyacetophenone(1.50 ml, 0.01M) and conc. sulphuric
acid (05ml) in gl. aceticacid (20ml) was reflux for 6 hrs. The reaction mixture
was poured into ice cold water. The product obtained was filtered, dried and
recrystallized from ethanol. Yield : 72%, M.P. : 204°C, (Required : C, 65.33%;
H, 4.98%; N, 13.85% for C22H20N4O2S, Found : C, 65.25%; H, 4.91% ; N,
13.76%).
TLC  solvent system Rf1 : Methanol : Chloroform          (2.0 : 8.0) = 0.64.
TLC  solvent system Rf2 : Methanol : Dichloromethane (1.5 : 8.5) = 0.72.
Similarly, other compounds (XIIa-j) were synthesized. The physical data
are recorded in Table No. XII.
(D) Antimicrobial activity of 3,6-Dimethyl-6-(substitutedphenyl)-1-phe-
nyl-1,5,6,7-tetrahydro-8H-pyrazolo [3',4':4,5] thieno [2,3-d] pyrimidin-8-
ones(XIIa-j).
Antimicrobial activity testing was carried out as described in part - I,
section - I, page No. 31.The MIC values of test solution are recorded in Table
No. XIIa, XIIb and XIIc.
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)






































IR  SPECTRAL  STUDY  OF   3,6-DIMETHYL-6-(p-NITROPHENYL)-1-PHE-
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)



































IR  SPECTRAL  STUDY  OF   3,6-DIMETHYL-6-(p-METHYLPHENYL)-
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)







































IR  SPECTRAL  STUDY  OF   3,6-DIMETHYL-6-(p-METHOXYPHENYL)-1-
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PMR  SPECTRAL  STUDY  OF   3,6-DIMETHYL-6-(2,4-DICHLOROPHENYL)-




















































































PMR  SPECTRAL  STUDY  OF   3,6-DIMETHYL-6-(m-NITROPHENYL)-1-























































PMR  SPECTRAL  STUDY  OF   3,6-DIMETHYL-6-(p-METHYLPHENYL)-1-




























































PMR  SPECTRAL  STUDY  OF   3,6-DIMETHYL-6-(p-FLUOROPHENYL)-1-

































































PMR  SPECTRAL  STUDY  OF   3,6-DIMETHYL-6-(p-METHOXYPHENYL)-1-



























































































































































































































m/z = 92 (M+1),
(XIIf)










































































































































m/z = 174 (M+1),


























m/z = 92 (M+1),
(XIIg)























































































































































m/z = 261 (M-1),
N
NH2 CH3










m/z = 43 (M+1) (B.P.),
CH4N2
(XIIi)








































































































































m/z = 257 (M+2),
CH3
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